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Methotrexate (MTX) suppressed the growth of Ehrlich
ascites tumour (EAT) cells in vivo. The rate of cellular
uptake of glucose and the number of glucose carriers, as
determined by cytochalasin B binding method, were also found
to be reduced. Administration of thymidine could partially
reverse the anti-tumour effect of methotrexate and
simultaneously this treatment could partially reverse the
reduction of the number of glucose carriers on tumour cells by
methotrexate. However, the administration of uridine
exhibited no effect on tumour cells.
The interferon inducers, polyriboinosinic: polyribo-
cytidylic acid (poly I:C), statolon and tilorone were found
significantly effective in arresting the Ehrlich ascites tumor
growth and also the inhibition of glucose transport activity.
Another interferon inducer, 2-aminoethylisothiouronium bromide
(AET), was found ineffective in suppressing tumour growth and
at the same time it was also ineffective in reducing the
glucose transport rate and the number of glucose carrier.
Intraperitoneal administration of inducers was found having
higher efficacy against tumor growth than other administration
routes. Pretreatment of poly I:C was also effective in
prevention of tumor growth and suppression of glucose carrier
number of tumour cells. The rather low titer of serum
interferon measured 24 hours after inducers administration
suggests that the inducers might also exert direct or indirect
2effects, besides through interferon, on the tumour cells.
Tumor necrosis factor (TNF) were cytotoxic to L929 cells
in vitro. [3H]-thymidine release from the cells was evident
as early as 12 hours after incubation with TNS. C. parvum-
induced TNS suppressed EAT growth and inhibited the glucose
uptake rate in vitro. In contrast, this TNS preparation
increased the glucose uptake rate of cultured L929 cells. TNS
preparations induced by zymosan and Listeria monocytogenes
could also increase glucose uptake rate of cultured L929
cells. The nature of cytochalasin B binding sites of L929
cells differed from that of EAT cells. The binding sites on
L929 cells were not glucose-reversible. Besides increasing
glucose uptake, TNS-treated L929 cells exhibited increases in
Ca 2+ uptake and uridine diffusion rate while the methionine
and leucine uptake remained relatively unchanged.
Studies of glucose transport system of EAT cells during
methotrexate, interferon inducers and TNS treatments in the
present thesis indicated that the magnitude of changes in
glucose-reversible cytochalasin B binding sites on EAT cell
surface was closely correlated with and sufficiently accounted
for the changes in the maximal rate of glucose uptake.
Michaelis constant (Km) for glucose uptake and apparent
dissociation constant (Kd) for cytochalasin B binding remained
relatively unchanged in all cases studied. This indicated
that there was no qualitative change in the turnover and/or
3of f init:y for glucose of the carrier of EAT cells during these
drug treatments. Our findings that the suppression of glucose
uptake of EAT cells by methotrexate were reversed by thymidine
administration and that the glucose uptake of EAT cells could
be inhibited by actinomycin D administration might suggest
that the inhibition of DNA, RNA and protein synthesis might
have constituted the primary chain of events leading to
reduced glucose carrier production in EAT cells during the
treatment of anti-tumor agents.
The binding of cytochalasin B on L929 cells, thymocytes,
spleen cells and macrophages of mouse could not be displaced
by high concentration of glucose in the incubation. These
observations might imply that cytochalasin B might not serve
as marker of glucose carrier of these cells.
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7CHAPTER ONE
VLUCOSE TRANSPORT IN L929 AND EHRLICH ASCITES TUMOR CELLS
ORIGIN OF EHRLICH ASCITES TUMOR
Ehrlich ascites tumor (EAT) was derived from a
spontaneous murine mammary adenocarcinoma (Ehrlich & Apolant,
1905) and was first converted from solid form into ascites
form by Lowenthal and Jahn (1932) and carried in outbred mice
the tetraploid subline Ny Klein strain which was established
by Klein and Klein (1956). Ehrlich ascties tumor cells can be
grown in mice and transplanted to permanent suspension culture
and vice versa. For in vivo studies, 10- 5 x 106 tumor
cells can be transplanted intraperitoneally into the mouse and
the maximal growth of tumor (about 2 x 10 9 cells) can be
attained 8- 9 days after tumor implantation. For the
passages of tumor cells in culture, 8- 10 fold dilution with
Fresh medium is performed every 3- 4 days. The limit for
hrlich ascites tumor cells grown in culture is about 106
Cells/ml and the generation time is quite constant with
iverage length of 22 hours before reaching the growth
plateau.
by serial intraperitoneal passage. In our laboatory, we use
8ORIGIN OF L929 CELLS
NCTC clone 929. was derived by Sanford, Earle and Likely
(1948) from the parental strain L established in 1940 by Earle
(1943). Strain L was one of the first cell strains to be
established in continuous culture, and clone 929 was the first
cloned strain developed. The parent L strain was dervied from
normal subcutaneous areolar and adipose tissue of a 100 day-
old male C3H/An mouse, and clone 929 was established by the
capillary technique for single cell isolation from the 95th
subculture generation of the parent strain. Since its origin,
the cells have been maintained in different media, exhibiting
different properties and were considered to be derivatives or
sublines. The monolayer L929 cells are cultured in RPMI 1640.
The passages of cells are carried out every 4- 5 days with
the help of trypsinization to round up and detach the cells
from the surface of the flask. The cells can be adjusted
again to 105 cells/ml and seeded into 25 cm2 culture flask.
The cells will resume the spindle shape and grow to confluency
after 3- 4 days.
GLUCOSE METABOLISM IN L929 AND EHRLICH ASCITES TUMOR CELLS
It has been as early as 1956 when Warburg discovered that
tumor cells usually have a characteristically distinct glucose
metabolism from those of normal cells. They mainly
metabolize glucose via glycolysis even in the presence of
oxygen. A term called 'aerobic glycolysis' was devised to
9signify this abnormal kind of glycolysis.
Ehrlich ascites tumor cells metabolize glucose to lactate
by means of this kind of aerobic glycolysis and were found to
have higher glucose uptake rate than normal cells (Crane,
Field Cori, 1957 Saha Coe, 1967 Rubin, 1971 Kaminskas,
1979). In later times, Ehrlich ascites tumor cells were found
to depend highly on glycolysis for generation of ATP (Lazo,
1981) and the deprivation of glucose supply brought forth a
decreased adenylate energy charge (Live kaminskas, 1975).
Little has been reported for the glucose metabolism of
L929 cells. It is generally believed that L cells can grow in
glucose limited medium provided they are supplied with other
essential elements (see Flow Manual, 1974).
GLUCOSE UPTAKE IN L929 AND EHRLICH ASCITES TUMOR CELLS
The glucose uptake in various tumor and normal cell lines
including Ehrlich ascites tumor cells is mediated through two
distinguished mechanisms, namely unsaturable diffusion and
saturable facilitated diffusion (Saha Coe, 1967 Kolber
Lefevre, 1967 Lieb Stein, 1970 Plagemann Richy, 1974
Hatanaka, 1974). Unsaturable diffusion is the simple
diffusion of glucose from extracellular environment into
intracellular environment due to the gradient between these
two environments. The saturable diffusion is thought to be
10
mediated by carrier molecules that reside on the cell membrane
and follows Michaelis-Menten kinetics. It may adequately
described by kinetic parameters Vmax (maximal rate of uptake)
and Km (apparent half-saturation constant). For the
measurement of these kinetic parameters, radioactive glucose
3 3
analogs (eg. 2-deoxy-D-[3H]-glucose, 3-0-methyl-D-[3H]-glucose
etc.) are employed in the experiments. Since the
radioactivity can be determined accurately and the glucose
analogs are non-metabolized, the parameters can be evaluated
with higher accuracy. Competitive inhibitors, for example
cytochalasin B, are used to determine the passive diffusion
due to the inhibition of carrier activity by these inhibitors.
The difference between the treatment with and without
inhibitors can be ascribed to the carrier-mediated uptake.
In the case of L929 cells, same rationale was employed
for the measurement of facilitated glucose uptake. Since the
cells are monolayer type, the glucose uptake experiments were
performed in wells of culture plate where L929 cells were
seeded. The results are expressed in nmoles 2-deoxy-D-glucose
uptake per mg protein.
CYTOCHALASIN B BINDING AND GLUCOSE CARRIERS
Cytochalasin B is a mold metabolite isolated from
Helminthosporium dematioideum (Mizel Wilson, 1972) and has
been shown to prevent motility and cytokinesis in eukaryotic
cells by destroying the integrity of microfilaments in the
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contractile ring (Carter, 1967 Schroeder, 1968 Wessells et
al., 1971). Besides the above effects, cytochalasin B was
found to be a potent and reversible inhibitor of glucose
uptake in animal cells (Kletzien, Perdue Springer, 1972
Czech, Lynn and Lynn, 1973). The examples are human
erythrocytes (Sogin and Hinkle, 1980), adipocytes (Karnieli et
al., 1981 Suzuki and Kono, 1980), chick embryo fibroblasts
(Salter Weber, 1979) and L6 myoblast (Klip, Logan Li,
1982). In 1974, Lin, Santi and Spudich have found two classes
of binding sites for cytochalasin B in bovine red blood cells,
HeLa cells and SV40 transformed mouse fibroblasts. One of
these two classes of binding sites can be inhibited by D-
glucose. This class of binging sites was termed 'glucose-
sensitive' binding. The 'glucose-sensitive' binding site has
been reported as being intimately related, if not identical to
the glucose carrier in the studies made by Pinkofsky et al.
(1978) and Jung and Rampal (1977). They found that in the
three types of cytochalasin B binding sites in human
erythrocytes, one of them, namely site I, was D-glucose
sensitive. The cytochalasin B binding system of human
erythrocytes have been purified (Kasahara Hinkle, 1977
Baldwin et al., 1979) and identified as glycoproteins with
apparent molecular weight of about 55,000. Reconstitution of
this purified cytochalasin B binding system on liposome
exhibited glucose transport activity and cytochalasin B
binding in the meantime (Kasahara Hinkle, 1977 Baldwin,
Gorga and Lienhard, 1981 Lundahl et al., 1981). This
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strongly indicated that cytochalasin B may be used as a
molecular marker for the glucose transport protein.
CHARACTERIZATION OF GLUCOSE SENSITIVE CYTOCHALASIN B
BINDING
Cuppoletti, Mayhew and Jung (1981) first characterized
the glucose carrier of Ehrlich ascites tumor cells and found
that cytochalasin B competitively inhibits the carrier-
mediated glucose transport of Ehrlich ascites tumor cells.
-7
The inhibition constant (Ki) they found was about 5 x 10 M.
They also found that cytochalasin E cannot inhibit the
carrier-mediated glucose transport. When the cytochalasin B
concentrations were up to 1 x 10-5, the range where the
inhibition develops to practical completion, three discrete
cytochalasin B binding sites with different dissociation
constants are distinguished (Table 1.1). These three binding
sites are called L, M, and H binding sites. The cytochalasin
B binding at L site shows a dissociation constant (Kd) of
about 1 x 10-6 M and represents about 30% of the total
6
cytochalasin B binding of the cell (8 x 10 molecules/cell).
The L-site binding is sensitively displaced by cytochalasin E
but not by D-glucose, and is located in cytosol. The
-7
cytochalasin B binding at M site shows a Kd of 4- 6 x 10 M,
7
represents about 60% of the total saturable binding (1 x 10
molecules/cell), is membrane-bound and specifically displaced
by D-glucose with a displacement constant of 15 mM, but not by
13
Table 1.1 Three Classes of Cytochalasin B Bindinq Sitesa
Apparent Sensitivity to
Class Dissociation % of Glucose Cytochalasin E
BindingConstant (Kd)
2- 6 x 10-8 MH 10 No No
-7
M 1- 6 x 10-7 M 60 Yes No
L 1 x 10-6 M No30 Yes
a Data from Cuppoletti, Mayhew and Junq (1981)
14
L-glucose, and is insensitive to cytochalasin E. The
-8
cytochalasin B binding at H sites shows a Kd of 2- 6 x 10-8
M, represents less than 10% of the total sites (2 x 106
molecules/cell), is not affected by either glucose or
cytochalasin E and is non-cytosol origin. The M site was
identified to be putative glucose carriers.
The binding of cytochalasin B to Ehrlich ascites tumor
cells was further characterized to have the following
properties (Chan et al., 1983 Chan, 1983)
(1) High affinity for cytochalasin B. The magnitude of Kd is
-7
10-7 M.
(2) Stereospecific inhibition by structurally related sugars
such as D-glucose, 3-O-methyl-D-glucose, 2-deoxy-D-
glucose, D-galactose and D-mannose, whereas L-glucose and
D-fructose are not effective.
(3) Sensitivity to other competitive inhibitors of glucose
transport such as phloretin and diethylstilbestrol.
It was found out (Chan et al., 1983) that the ability of
Ehrlich ascites tumor cells to take up glucose increases
progresively during the course of tumor development.
Simultaneously, the density of glucose-sensitive cytochalasin
B binding sites on the cell surface also increases. Since Km
for uptake and Kd for binding remain unchanged throughout the
course of tumor development, it appears that the changes in
glucose transport by Ehrlich ascites tumor cells are
15
principally the result of changes in the number rather than in
the affinity of transport carriers. Since there is a
continuous fall of serum glucose level in tumor-bearing mice
during tumor development (Pavelic et al., 1979 Chan et al.,
1983), it is suggested that tumor cells compensate for the
deficiency in glucose availability by increasing the number of
glucose carriers (Chan et al., 1983). It was discovered that
the suppression of Ehrlich tumor growth by many drugs such as
methotrexate (Chan et al., 1983), N-(phosphonacetyl)-L-
asparate (PALA) (Leung et al., 1984) and tumor necrosis factor
(TNF) (Fung et al.., 1985) paralleled with the suppression of
maximal glucose uptake (Vmax) and the number of glucose-
sensitive cytochalasin B binding (Bo) of the cells. This may
suggest the importance of glucose transporter in Ehrlich
ascites tumor cells and explain the tumor suppressing effects
of these anti-tumor drugs.
Besides the majority of tumor cells, there are also some
minorities of fat cells, red blood cells, tumor cell debris,
immunologic macrophages and leucocytes present in the ascitic
fluid. Fat cells and red blood cells have been reported to
have glucose uptake ability (Kono et al., 1981 Resh, 1982
May, 1982 Pinkofsky et al., 1978). However, data concerning
tumor cell debris, macrophages and leucocytes are lacking. In
our experiments, we have applied steps to remove these cells
from EAT cell preparation (see Chapter 3) so that their
capacity of binding with cytochalasin B, if any, might not
affect our estimation of glucose carrier on EAT cells.
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However, it is still of interest to test whether these cells,
if were not completely removed, could affect cytochalasin B
binding on EAT cells. In pilot experiments, we studied the
binding of cytochalasin B on these cells. The experiments on
macrophages and leucocytes indicated that macrophages and
leucocytes belong to a class of cells whose glucose carrier
density cannot be estimated by cytochalasin B method (see
Appendix I). Table 1.2 shows the results of glucose-
sensitive cytochalasin B binding to dead Ehrlich ascites tumor
cells. The number of functioning binding sites have been
reduced to one-fifth of control value. Hence, a tentative
conclusion has been drawn that dead EAT cells, macrophages and
leucocytes in ascitic fluid could not affect our glucose-
sensitive cytochalasin B binding on EAT cells.
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Table 1.2 The glucose-sensitive cytochalasin B binding
a
of dead Ehrlich ascites tumor cells a
Groups Bo Kd
(pmoles/10 7 cells) (10-7 M)
EAT Cells 235.8+ 5.87 2.20+ 0.7
Dead EAT Cells 46.1+ 4.65 3.71+ 0.6
a The detailed procedures for cytochalasin B binding are
described in Chapter 3.








The tumor cells, like other cells, have many glucose
carriers on their cell surface and depend highly on glucose
for energy metabolism. Ehrlich ascites tumor cells have a
high ability in metabolizing glucose to lactic acid by
glycolysis (Warburg, 1956). It has been found out that
Ehrlich ascites tumor cells contain a large amount of a kind
of glucose-sensitive cytochalasin B binding sites which are
closely related or even identical to the glucose carriers
which are responsible for the carrier-mediated uptake of
glucose (Cuppoletti, Mayhew & Jung, 1981). The content of
these binding sites in Ehrlich ascites tumor cells is at least
4-fold greater than that of transformed chicken embryo
fibroblasts (Salter & Weber, 1979) and that of human
erythrocytes (Jung & Rampal, 1977). The high content of
glucose carriers may be responsible for its tumor nature and
any interference of the glucose transport system may affect
the survival of tumor cells.
We have reported that Ehrlich ascites tumor cells are
susceptible to many anti-tumor agents like methotrexate (MTX)
(Chan et al., 1983), 1,3-bis(2-chloroethyl)-l-nitrosourea
(BCNU) (Leung et al., personal communication), N-
(phosphonacetyl)-L-aspartate (PALA) (Leung et al., 1984) and
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tumor necrosis factor (TNF) (Fung et al., 1985). These agents
can also decrease the glucose uptake rate of the cells. To
investigate whether reduction of glucose transport of tumor
cells is a common mechanism of anti-tumor agents, the effect
of some interferon inducers, which have been found effective
against many tumor cell lines (Levy et al., 1970;
Kleinschmidt, 1972), on the glucose transport system of
Ehrlich ascites tumor cells were examined.
In our previous study of the effect of methotrexate and
PALA on glucose carrier of Ehrlich ascites tumor cells, we
have suggested that the inhibition of DNA, RNA and protein
synthesis might have constituted the primary chain of events
leading to reduced glucose carrier production in tumor cells
(Chan et al., 1983, Leung et al., 1984). In the present
thesis, we planned to examine this hypothesis. Since
methotrexate can produce a "purineless" state in the tumor
cells (Hryniuk, 1972), supplementation of purine or pyrimidine
might reverse the anti-tumor effect of methotrexateo And
besides, the supplemented purine or pyrimidine might also used
by the cells as sources for DNA and RNA synthesis. If our
hypothesis reveals the true situations of control of glucose
carrier in Ehrlich ascites tumor cells, a reverse of
suppression of glucose carrier by methotrexate should be
observed when thymidine or uridine were co-administered to
methotrexate-treated tumor-bearing mice. To further examine
the above hypothesis, the effect of actinomycin D and
cvcloheximide, which are inhibitors of RNA and protein
20
synthesis respectively, on glucose transport of Ehrlich
ascites tumor cells in vivo were tested.
We have investigated the effect of tumor necrosis factor
on Ehrlich ascites tumor cells (Ha et al., 1984a Ha et al.,
1984b Fung et al., 1985). We have found that.tumor necrosis
serum could suppress growth of Ehrlich ascites tumor cess in
vivo and in vitro. As the tumor growth was suppressed, the
glucose transport was also reduced. By using cultured L929
cells as a model, we planned to study, in addition to effect
on glucose transport, other effects of these nucreosis
factors, namely Ca2+, uridine and amino acid uptake on tumor
Throughout our studies of glucose transport and glucose
Carrier on tumor cells, we used the conventional cytochalasin
3 binding method to elucidate the glucose transport mechanism
of the cells (see Chapter 1). In view of a recent report by
filbert (1984) which reveals that cytochalasin B does not serve
as a marker of glucose transport in rabbits and erythocytes,
we examined the binding of cytochalasin B to various mouse
--ells with the hope to investigate whether cytochalasin B is
an universal ligand for glucose carrier in the cells. The
mouse normal cells used were thymocytes from the thymus,
spleen cells from the spleen and macrophages from the C.
parvum-stimulated peritoneal fluid. The mouse tumor cells
used was cultured L929 cells. Results of cytochalasin B
cells.
21
binding of these cells would be compared with those of




All the materials used and general methods are described
here. However, some specific methods or procedures may be in
the EXPERIMENTAL section of the related chapter.
MATERIALS
All the chemicals and materials listed below were of
"Analytical Reagent (AR)" grade unless otherwise stated.
Chemical Supplier
-albiochemo2-aminoethylisothiouronium bromide (AET)
Calcium-45 Calcium chloride in aquo solution kmersham
(1602 uCi/mM)
Calf serum Gibco
MerckCopper (II) sulphate pentahydrate
Wellcome Lab.Corynebacterium parvum
Cytochalasin B Sigma
[ 3 H]-Cytochalasin B (7e2 Ci/mmol) N E N
2-Deoxy-D-glucose Sigma
2-Deoxy-D-E 3 H]-glucose (1602 Ci/mmol) Amersham
SigmaDipyridamole












L-[U- C]-Leucine (342 mCi/mmol) Amersham
3
L-[4,5- H]-Leucine (50 Ci/mmol) Amersham
Lipopolysaccharide (from E. coli) Sigma
(Serotype 0127:B8)
























Streptomycin (10,000 ug/mi) Gibco
Thymidine Sigma






[5- H]-uridine (2804 Ci/mmol) Amersham
SigmaZvmosan
Ajax: Ajax Chemicals, Australia.
Amersham: Amersham International Ltd., England.
BDH: British Drug House Chemical Ltd., England.
Calbiochem.: Calbiochem. (La Jolla, CA) Behring Corp., (Ta
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Jolla, Calif).
C. M. L.: Clinical Microbiology Lab., Queen Mary Hospital,
University of Hong Kong.
Lederle: Lederle Parenterals, Inc. Carolina, U.S.A.
Lilly: Lilly Laboratories, Eli Lilly & Co., Indianapolis).
Mallinckrodt: Mallinckrodt, Inc., U.S.A.
Merck: E. Merck, F.R.G.
N E N: New England Nuclear, U.S.A.
Peking: Peking Chemical Works, Peking, China
R. de Haen: Riedel. de Haen, F.R.G.
Sigma: Sigma Chemical Co., U.S.A.




ICR strain of mice (30-35 g) were used. They were kept in
air-conditioned rooms and fed standard laboratory 'chow' and
tap water ad libitum.
Maintenance of Erlich Ascites Tumor Cell Line
A. In vivo maintenance of tumor cell line
Erlich ascites tumor, Ny Klein cell type, was maintained
by intraperitoneal implantation in mice. Mice bearing 7-day
old tumors were killed by cervical dislocation. Ascites fluid
containing tumor cells were collected from peritoneal cavity
by aspiration and diluted with phosphate buffered saline
(PBS). The cells were collected by a table-top clinical
centrifuge. The cells were then washed 5 times with half-
isotonic saline to get rid of the blood cells and resuspended
7
in PBS to 5 x 10 cells/ml. 0.2 ml cell suspension containing
7
10 cells was injected intraperitoneally into the normal mice.
B. In vitro culture of tumor cells
Operations: All manipulations of cell culture were performed
under a laminar flow hood (Baker) with sterilized instruments
and glassware.
Preparation of Culture Medium e The growth medium for all
cell culture in our experiments was RPMI 1640. The medium was
prepared with double-distilled water and supplemented with 25
27
mm HEPES and 25 mM NaHCO3 according to the manufacturer's
specifications. The medium was sterilized by passage through
a 0.45 um Millipore filter and stored at 4°C. Sterility was
tested by incubating the filtered medium in culture tubes at
°
37 C for 3 days. When use, the medium was supplemented with
50 units/ml penicillin, 100 ug/ml streptomycin and 10% (v/v)
heated-inactivated fetal calf serum or calf serum which had
been incubated at 56 °C for 30 min.
Primary Culture: The culture of Ehrlich ascites tumor cells
was established by collection of cells asceptically from tumor
bearing mice, and immediately washed twice with sterile PBS.
The washed cells were then resuspended in complete RPMI 1640




After incubation at 37 C for 24 hours, the suspended cells
were collected and seeded into new flasks. The same procedure
was repeated twice and the cells were then passaged routinely.
Routine Passages of Cells: Ehrlich ascites tumor cells in
culture were passaged every 3-4 days by 10 fold dilution with
fresh culture medium. Cells between 16-50th passages were
used for experiments.
Maintenance of L929 Cells
The growth medium used is the same as in the culture
experiment of Ehrlich ascit.es tumor cells. 105 L929 cells,
were seeded into 25 cm2 culture flask and passaged routinely.
Rountine Passage of L929 Cells: L929 cells were passaged
every week. The medium was removed from the culture flask and
28
0.25% trypsin solution was added adequately to cover the
O
monolayer of cells. After incubation at 37 C for 1 minute,
the cells became detached from the surface of the flask. The
cells were resuspended with growth medium and any aggregation
of cells were broken down by a pipette. The viable cells
were counted by trypan blue exclusion method and cell
5
concentration was adjusted to about 10 per ml and incubated
0
at 37 C in 0.5% CO.
2-Deoxy-D-['H]-glucose Uptake of Ehrlich Ascites Tumor Cells
The method as described in Leung et al. (1984) was
7
followed. Ehrlich ascites tumor cell suspension (2 x 10 /ml)
in PBS) were equilibrated to 37°C. At zero time, 0.2 ml cell
suspension was mixed with 0.2 ml of pre-warmed 2-deoxy-D-[3H]-
glucose (1 uCi/umol) to give final concentrations of 0.1875 to
1.0 mM. Reaction was stopped after 6 sec by transferring 0.2
ml of mixture to 1 ml ice-cold PBS supplemented with 20 mM 2-
deoxy-D-glucose. Cells were collected by centrifugation at
15,000 g for 10 sec in an Eppendorf 5414 microcentrifuge. The
supernatant was removed by aspiration and the cells were
washed with 1 ml of the same buffer. Cell lysis was
accomplished by the addition of 0.2 ml 0.1% Triton X-100. One
ml of Triton X-toluene scintillant was added and the
radioactivity counted in a Beckman LS-7000 liquid
scintillation counter. Non-specific diffusion was corrected
by subtracting the uptake in the presence of 10 uM (final
concentration) cytochalasin B. The kinetic parameters Vmax
29
and Km, representing respectively the maximal uptake rate and
apparent half-saturation constant for the specific transport
process, were determined by double-reciprocal plot.
2-Deoxy-D-[JH]-glucose Uptake of L929 Cells
105 L929 cells, in 0.5 ml complete RPMI 1640 medium, were
seeded into each well of a 24-well plastic tissue culture
plate (Falcon). The monolayer of L929 cells was then washed
twice with PBS (pH 702) and equilibrated to 37 0C. At zero
time, 0.5 ml prewarmed 2-deoxy-D-[3H]-glucose (1 uCi/umol) in
PBS was added to give final concentrations of 0.5- 3.0 mM.
Reaction was stopped after 5 min by aspirating off the medium
and rapid washing the cells three times with 1 ml ice-cold PBS
supplemented with 40 mM cold 2-deoxy-D-glucose or 10 mM 2-
deoxy-D-glucose supplemented with 100 mM D-glucose. The cells
were lysed by addition of 0.5 ml 0.1% Triton X-100 to
individual well. Radioactivity of the lysate was counted in a
Beckman LS-7000 liquid scintillation counter. Protein was
determined by Lowry°s method (Lowry et al., 1951).
The initial rate of uptake was plotted against the
concentrations of 2-deoxy-D-glucose. The extent of the
diffusion-mediated uptake was estimated graphically by drawing
a line through the origin and parallel to the linear portion
of the total uptake curve (Renner, Plagemann & Bernlohr, 1972;
Plagemann Richey, 1974). The uptake rate due to the
transport reaction was obtained by subtracting the estimated
diffusion rate due to the unsaturable component from the
overall rate. The corrected rates showed the Michaelis type
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kinetics and the kinetic parameters Vmax and Km were
determined.
Equilibrium Binding of Cytochalasin B of Ehrlich Ascites
Tumor Cells
Equilibrium binding of cytochalasin B was performed
according to Cuppoletti, Mayhew and Jung (1981) with minor
modifications (Chan et al., 1983). For measuring total
binding, 107 cells in 1 ml PBS were incubated with 0.04 uCi
[ 3H]-cytochalasin B and 1 x 10-7- 5 x 10-7 M cytochalasin B
for 20 min at room temperature. After the incubation, the
cells were collected by centrifugation at 15,000 g for 20 min.
The radioactivities of supernatant and pellet fractions were
determined.
Cytochalasin B bound was calculated as% of total. To
assess the glucose-reversible binding of cytochalasin B, total
binding in the absence and presence of 500 mM D-glucose were
measured and the difference obtained. Maximal glucose-
sensitive binding (Bo) and the apparent dissociation constant
(Kd) were determined by Scatchard analysis.
Measurement of Leucine, Uridine and Thymidine Incorporation
in Ehrlich Ascites Tumor Cells
Ehrlich ascites tumor cells were washed three times with
sterile PBS and resuspended with culture medium to 10 6
cells/mi. 100 ul cell suspension was added into each well of
a 96-well micro-titer plate (Falcon) and then mixed with 100
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ul [3H]-leucine, [3H]-uridine and [3H]-thymidine (10 uCi/ml).
After incubation at 37°C for 2 hours, the cells were harvested
with saline through GF/C filter by cell harvester. The filter
was subsequently washed with 5% trichloroacetic acid (TCA) and
absolute methanol. Filters were dried in air and placed in
scintillation vials containing 3 ml toluene-scintillant. The
radioactivities were measured with a Beckman LS-7000 liquid
scintillation counter. Background adsorption of radioactivity
was corrected by addition of radioactive precursors after
incubation and immediately before the harvest of cells.
Interferon Assay
The assay was based on the method of inhibition of
cytopathic effect (CPE) (Armstrong, 1981). The virus-cell
system employed was vesicular stomatitis virus (VSV)- L929
cells. 0.05 ml medium containing 2 x 104 L929 cells was added
to the well of 96-well flat-bottomed plate. After 3 hr of
0
incubation at 37 C with 5% CO, 0.1 ml of appropriately
2
diluted serum was added to the wells in duplicate. The tray
0
was then incubated overnight at 37 C with 5% CO
2
Growth medium was then removed and the cell monolayer was
washed three times with warm PBS (or MEM). 0.1 ml of VSV
suspension containing a standard challenge dose of 6 TCID
50
was added to all test wells. Virus control wells received the
challenge dose of VSV, whereas the cell control wells received
an equal volume of maintenance medium only.
A standard interferon preparation with known NIH units/ml
which consistently gave a fixed titer was included in each
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assay. Assays were done in duplicate.
The tray was then re-incubated and the result was read
after 24 hr of incubation at which time the cell monolayer in
the virus control wells showed 100% CPEO
*: Determination of 50% Tissue Culture Infective Dose (TCID)
50
of VSV was performed by first serially diluted the VSV 3
fold in maintenance medium and 001 ml aliquots of each
dilution were added to a group of 5 wells cells. The tray
was then re-incubated and the result was read 24 hr later.
Wells in which 50% or more of the cell monolayer showing
cytopathic effect (CPE), characterized by cell rounding,
were regarded as positive. The TCID was calculated by
50
the method of Reed and Muench (1938).
Determination of Cell Count and Viability
Cell suspension of appropriate dilution was introduced
onto the ruled counting area of a haemocytometer (American
Opticals) under the coverslip. The number of cells was
counted with a phase contrast microscope (Nikon) using the
tally counter to record numbers. Cell concentration in
original suspension was calculated accordingly. For the
determination of cell viability, the cells were stained with
0.5% trypan blue, and the unstained (viable) and stained
(dead) cells were counted. Hence, the viability is calculated
from:
No- of viable cells
x 100%Viability
Total no. of cells
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CHAPTER FOUR
EFFECTS OF THYMIDINE AND URIDINE RESCUE ON TUMOR GROWTH AND
GLUCOSE TRANSPORT IN METHOTREXATE TREATED EAT CELLS
INTRODUCTION
ANTICANCER ACTION OF METHOTREXATE
Methotrexate is a most widely used anti-metabolite in
cancer chemotherapy. It is the 4-NH 2,N-10 methyl analogue of
a class of essential cofactors called folate vitamins. The
folate vitamins have to be reduced to tetrahydro form before
they are biologically active. The tetrahydrofolates then
receive one-carbon groups from other sources to generate the
folate coenzymes. The folate coenzymes can donate their one-
carbon groups to the biosynthetic reactions of thymidylic acid
and purines, which are essential for DNA synthesis and cell
division (Stokstad and Koch 1967).
Methotrexate is one of the antifolate agents which were
put for clinical use in 1948. Antifolate agents inhibit the
vital functions of folate coenzymes and hence cause a
cessation of the processes of DNA synthesis and cellular
replication. Many actively proliferating tissue, especially
the malignant cells, have a higher rate of DNA synthesis and
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cellular replication and are more susceptible to the effects
of antifolates.
The structures of physiological folate cofactors and
methotrexate are shown in Fig. 4.1. They share common
structural features: a multi-ring pteridine group linked to a
para-aminobenzoic acid and then to a terminal glutamic acid
residue. Most intracellular folates are converted to
polyglutamate forms, containing multiple glutamate groups
linked by gamma-peptide bonds. The polyglutamate forms of
folic acid are preferentially retained inside the cells and
are usually more efficient cofactors than the monoglutamated
compounds (McGuire Bertino, 1981)° Like the physiologic
folates, methotrexate is extensively metabolized
intracelluarly to polyglutamate derivatives. The common
structure between methotrexate and physiologic folates renders
methotrexate the ability of competitive inhibition of
reductase for the generation of tetrahydrofolateo Jolivet et
310 (1983) stated in their review of methotrexate that the
Dolyglutamates formation of methotrexate causes the drug to be
Dotentially less reversible inhibitor, to have longer
retention within the cells, and to have broader range of
inhibition on other folate-requiring enzymes.
The current concept of the methotrexate's mechanism of
action is illustrated in Fig. 4.2. Methotrexate enters cells
through the active transport system used by the physiologic
circulating folate N5-methyl-FH 4 and N5-formyl-FH 4 (leucovorin
and folinic acid) and also by passive diffusion when at high
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concentrations.
After entering the cells, methotrexate quickly binds to
and inactivates dihydrofolate reductase. This enzyme has a
crucial role in maintaining intracellular tetrahydrofolate
pools by reducing dihydrofolic acid, which is produced during
thymidylate synthesis. The critical result produced by
inhibition of dihydrofolate reductase is depletion of
intracellular pools of reduced folate. The reaction most
sensitive to folate depletion is thymidylate synthesis, which
requires N5-10 meth lene-FH . This reaction ceases at
4
concentrations of 0.1 nM of methotrexate (Chabner & Young,
1973). Another folate, N10-formyl-FH 4, involved in both
folate-dependent steps of purine synthesis, is also depleted
at approximately 001 uM of methotrexate (Smith et al., 1981).
The lack of either thymidylate or purines blocks the synthesis
of DNA. Cellular proliferation in malignant tissue is greater
than in normal tissue and thus methotrexate impairs malignant
growth more pronouncedly.
EFFECTS OF METHOTREXATE ON TUMOR GROWTH AND GLUCOSE TRANSPORT
OF EHRLICH ASCITES TUMOR CELLS
The primary anticancer action of methotrexate is the
inhibition of folate reductase and the impairment of
thymidylate and purine synthesis, which in turn affects the
DNA synthesis and cellular proliferation. The polyglutamate
derivatives of methotrexate are important for the prolonged
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Fig 4.1 The structure of tetrahydrofolate (A) and
methotrexate (B) polyglutamates.
In Panel A, one-carbon groups (R) are
transported on nitrogen 5 or 10 or both.
Pteridine ring p-Aminobenzoic acid Glutamyl residue
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Fig. 4.2 Biochemical pathways involved in the action of
methotrexate and the modulation of
methotrexate toxicity by thymidine.





























inhibition of dihydrofolate reductase and extended
cytotoxicity (Jolivet et al., 1983)° Fabres and Goldman (1984
reported that when Ehrlich ascites tumor cells were incubated
with 5 uM of MTX,- MTX polyglutamyl derivatives accumulated
within the cells. They related the content of these
polyglutamyl derivatives in the tumor cells to the
cytotoxicity of methotrexateo
Kaminskas and Nussey (1978) found that glycolytic rate of
Ehrlich ascites tumor cells decreased with methotrexate
treatment. Adenylate pools and adenylate energy charge were
also decreased in cells isolated in methotrexate containing
medium in vitro. Since Ehrlich ascites tumor cells are
highly dependent on glycolysis for their energy metabolism,
the impairment of DNA synthesis may accompany by a severe
inhibition of ATP regeneration.
We (Chan et al., 1983) have also studied the effect of
MTX on the glucose transport system of EAT cells. MTX
arrested EAT growth, inhibited glucose uptake, and reduced the
number of glucose carrier. In both MTX-treated and untreated
cells, the magnitude of changes in glucose carriers closely
paralleled and sufficiently accounted for the magnitude of
changes in glucose uptakes. The qualitative changes in the
turnover and affinity for substrate of the glucose carrier was
minimal.
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THE REVERSAL OF METHOTREXATE TOXICITY BY THYMIDINE
The major action of methotrexate is the inactivation of
the enzyme dihydrofolate reductase and hence the blockage of
the process of dihydrofolic acid to tetrahydrofolic acid.
Since intracellular dihydrofolic acid is produced only during
thymidylate synthesis. The underlying rate of thymidylate
synthesis is an important determinant of cytotoxicity (Moran
et al., 1979)0
Borsa and Whitmore (1969) showed that MTX toxicity toward
mouse L cells in vitro was enhanced by simultaneous addition
of purine. This suggested that in L cells MTX led to
depletion of both thymidine 5'-triphosphate (dTTP) and
purines, and addition of purine resulted in a more lethal
selective depletion of dTTPO In contrast with those results,
Hakala (1957) reported that the inhibition of methotrexate on
DNA synthesis could be prevented in cell culture by supplying
the other end products of folate metabolism such as thymidine
and hypoxanthine to medium which contains methionineo Hryniuk
et al. (1969) found that MTX induced a lethal purineless state
in L5178Y mouse lymphoma, and the antipurine effect was
greatest in cells of rapid growth rate (1972). Tattersall et
ale (1974) attributed the correlation between growth rate and
the antipurine effect of 'MTX to the higher activity of
thymidylate synthetase in the rapidly growing cells, which
would result in faster depletion of the tetrahydrofolate
cofactor pools necessary for de novo purine biosynthesis.
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Hoglind-Semon Grindey (1978) proposed that the mechanism of
the partial protection induced by thymidine may be due to the
modulation of thymidylate synthetase activity by thymidine-
derived increases in the intracellular pool of dTTPO Upon
metabolic conversion to dTTP, thymidine may decrease the rate
of thymidylate synthetasem As the reaction catalyzed by
thymidylate synthetase is the only reaction which converts
reduced folates to dihydrofolate, the decrease of thymidylate
synthetase activity will not deplete the reduced folate
cofactors pools. Under such conditions no purine toxicity
will be expressed.
The modulation of methotrexate toxicity by thymidine has
been further proved by Jackson (1980) in his research with
mammalian fibroblasts, lymphoblasts, and N1S1 tumor cells. He
stated that thymidine not only overcame the antithymidylate
effect of MTX, but also antagonized the antipurine effect.
AIM OF STUDY
In pilot studies, we have observed the effect of
thymidine on the reversal of cytotoxicity of MTX on EAT cells.
In our previous experiments (Chan et al., 1983) on studying
the effect of MTX on the glucose transport system in EAT
cells, we observed that MTX reduced the number of glucose
carriers on the cells. The efficacty of the drug in this
respect roughly paralleled its efficacy in reducing tumor
size, suggesting that MTX-induced depletion of nucleotides and
the consequent inhibition of DNA, RNA and protein synthesis
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might have constituted the primary chain of events leading to
reduced carrier production. We planned to alleviate the anti-
tumor effect of MTX on EAT cells by coadministration of
thymidine in vivo and in vitro and to examine whether this




PREPARATION OF DRUG SOLUTION
Methotrexate (5 mg vial) was reconstituted with 2 ml of
sterile water and stored at -20 °C. The solution was sterilized
by passage through 0.45 um millipore filter. For in vivo
studies, the reconstituted solution might be diluted with
saline (0.85% NaCl).and used directly for injections. For in
vitro studies, the solution was further diluted with culture
medium to desired concentrations just before use.
TREATMENT OF TUMOR BEARING MICE
Mice were inoculated i.p. with 107 ascites tumor cells
harvested from 7-day old tumors in 0.2 ml phosphate-buffered
saline, pH 7.4 (PBS), on day 0. The effects of methotrexate
and nucleosides were observed in groups of at least 10 mice
each. In the test groups, methotrexate (1.7 mg/kg body
weight) and/or thymidine/uridine (20 or 200 mg/kg body
weight) were administered intraperitoneally on days 2,4 and 6
inclusively. The mice were killed by cervical dislocation on
day 7. Tumor cells were washed 5 times with half-isotonic
saline to remove blood cells and harvested by centrifugation.
The final cell suspension was prepared in phosphate-buffered
sa1inP (PRS)e Cells were counted with a haemocvtometer and
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resuspended in the same buffer to 2 x 107 cells/mlo Glucose
uptake and cytochalasin B binding were then measured. For the
incorporation of leucine, uridine and thymidine, the cells
were resuspended in PBS to 106 cells/ml.
TREATMENT OF TUMOR CELLS IN CULTURE
To investigate the effect of methotrexate and/or
thymidine on tumor growth in culture, 5 x 10 5 cells/ml were
seeded into culture.flaskso In the test groups, Om02-20 uM
methotrexate and/or 40 uM thymidine were supplemented into the
culture medium. Clumps of cells were disaggregated by gentle
pipetting and 0.2 ml aliquot of cell suspension was taken for
cell counting. The viability was assessed by trypan blue
stain.
For the study of glucose uptake, 5 x 105 cells/m1 was
seeded and incubated with 2 uM methotrexate or 40 uM thymidine
in medium for 24 hours. For the reversal test, the cells were
incubated with 40 uM thymidine for 2 hr before the
supplementation of 2 uM methotrexate° Cells were then
collected by centrifugation at 1,000 g for 5 min and washed
twice with PBS. 2-deoxy-D-glucose uptake was determined as
described in Chapter 3.
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RESULTS
IN VITRO AND IN VIVO EFFECTS OF MTX ON GROWTH OF EAT CELLS
Fig. 403 shows the suppressive effect of different doses
of methotrexate on Ehrlich ascites tumor size in vivo. Fig.
404 shows the suppressive effect of methotrexate( 2 and 100
um respectively) on tumor growth and viability of EAT cells
in vitro.
EFFECT OF THYMIDINE ON TUMOR GROWTH OF METHOTREXATE TREATED EAT
Both the in vivo and in vitro reversal effects of
thymidine on MTX treated EAT cells were examined. The
administration of thymidine( 10-100 mg/kg) can reverse the
suppressive effect of methotrexate( 1.7 mg/kg) on tumor
growth in vivo (Fig. 4.5). However, the reverse is a maximum
During low doses of thymidine( at the range of 20 to 40 mg/kg
). At 30 mg/kg dose, thymidine could almost reverse the
cytotoxic effect of methotrexate. When at higher doses, eg.
100 mg/kg, thymidine could only alleviate about 56% of the
inhibition of tumor growth by methotrexate. A typical example
of the thymidine effect on tumor size of methotrexate treated
mice is shown in Table 4.1. Thymidine (20 mg/kg) has no
effect on growth of EAT cells (P 0.05). However, when
thymidine was co-administered with MTX it could alleviate the
suppressive effect of MTX on EAT growth.
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Fig. 4.3 Dose response curve of the tumor size of EAT to
different doses of methotrexate in vivo.
Each group consisted of 10 mice. Each mouse
was inoculated with 107 cells on day 0. On
days 2, 4 and 6, the mice received i.p.
injection of indicated doses of methotrexate.
On day 7, the mice were sacrified and the cells
were'collected for cell count. The results are
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Fig 4.4A The effect of methotrexate doses: nil(.__.),
2 uM (0_0) and 0.1 mM ( ) on total cell
population of EAT cells in vitro.
4.4B The effect of the above doses of methotrexate
on the viability of EAT cells in vitro.
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Fig. 4.5 Effect of thymidine on methotrexate treated EAT cell
growth in vivo.
107 EAT cells were inoculated imp. into the
peritoneal cavities of each group (10 mice) on
day 0. 0.2 ml of saline with different dosages of
thymidine( 10-100 mg/kg) were injected i.po with/
without O.2 ml of methotrexate( 1.7 mg/kg) on day
2, 4 and 6. On day 7, the mice were killed and the
cells counted.
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Table 4.1 The reversal effect of thymidine (20 mg/kg) on
tumor size of methotrexate (1.7 mg/kg) treated
a
tumor-bearing mice.a
significance.bGroups Tumor size (10 8 /mouse)
12.36+ 2.57Control
5.28+ 0.61 P < 0.001MTX
P<0.019.76+ 30.8MTX+ Thymidine
P >0.0510.07+ 2.73Thymidine
a Each group consisted of 10 mice. The mice were
7
inoculated with 107 cells on day 0. On days 2, 4
and 6, the mice received i.p. injection of indicated
doses of drugs. The mice were sacrified on day 7.
The results are presented as mean± S.E.M. for 2
experiments.
b The significance of each group was set for compari-
sion with control, except that the value for MTX+
Thymidine was set for comparison with MTX group.
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Thymidine also showed positive result in in vitro study
(Fig. 4.6). The cells population reduced with increasing
doses of methotrexateo The inhibition of cell growth was
significant when MTX dose reached 2 uM. It is specially
interested to note that the viability of cells became
significantly decreased after 50 hours incubation with MTX
(Fig. 4.6 B). However, co-incubation with thymidine (40 uM)
and MTX could reverse the inhibition of methotrexate on tumor
growth (Fig. 4.6A) and the viability of tumor cells were also
:onserved (Fiq. 4.6B).
EFFECT OF MTX ON GLUCOSE TRANSPORT OF EAT CELLS IN VITRO
Table 402 shows the effect of methotrexate( 1.7 mg/kg)
on glucose transport kinetics and cytochalasin B binding of
cultured EAT cells. We have found that methotrexate
suppressed the glucose transport and glucose carrier of EAT
cells in vivo (Chan et al., 1983). In the present experiment,
we further demonstrated that MTX could significantly reduce
the maximum 2-deoxy-[3H]-glucose uptake rate (Vmax) (P < 0.05)
and the number of glucose carriers (Bo) (P <0.001) in vitro.
However, this treatment did not affect the values of Km of
uptake and Kd of cytochalasin B binding and these
observations are also consistent with data of in vivo studies
(Chan et al., 1983).
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Fig. 4.6 Effect of thymidine on tumor size and viability
of methotrexate treated EAT cells in vitro.
5
A. 2 x 105 cells/ml of EAT cells were seeded in 25
cm2 culture flasks. Total cells in the culture
incubated with MTX at indicated concentrations
at 26 hr( ), or at 50 hr ( ), or with 40
uM thymidine and different concentrations of
MTX at 26 hr (O -0), or at 50 hr ( - ) were
assessed.
B. The viability of the treated cells were
assessed by trypan blue exclusion method. Same
notation as in Fig. 4.6 A.
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Table 4.2 The effect of methotrexate on the glucose
transport of EAT cells in vitro.a
2-deoxy-D-glucose uptake Cytochalasin B binding
Groups Vmax Km Bo Kd
(nmol/min/106 cells) (mM) (pmol/107 cells) (10-7M)
18.76±0.82 0.97±0.06 235.8±6Control 2.2±0.7
# P > 0.2
15.89+0.77*MTX 0.91±O.08# 151.6+14** 2.7+0.4 #
a The cells in MTX group received 2 uM MTX in medium for
24 hours. The control group received normal RPMI
medium. Then the cells were collected for uptake and
binding experiments as described in Chapter 3. The
results presented as mean+ S.E.M. of 3 determinations
in 2 separate experiments.
b The significance was determined by Student's t-test.
* P < 0.05
** P < 0.001
59
REVERSAL EFFECT OF THYMIDINE ON GLUCOSE TRANSPORT OF EAT CELLS
The reversal effect of thymidine on glucose transport
kinetics and cytochalasin B binding of EAT cells was
investigated in tumor bearing mice (Table 4.3). The effect of
the drugs caused a similar extent of change in both glucose
uptake and cytochalasin B binding activities. While
methotrexate caused about 25% reduction in both glucose uptake
and cytochalasin B binding, the administration of thymidine at
the same time brought the glucose transport activities back to
the control levels (P< O.05). Thymidine alone showed about
97% of the control levels (P >0.1).
The thymidine effect was also assessed by in vitro
study. Since the effects of drugs on the glucose uptake of
EAT cells as shown in Table 4.3 paralleled to those on
cytocyalasin B binding, we only examined the glucose uptake
rate in in vitro studies. The data of 2-deoxy-D-glucose
uptake (Table 4.4) showed the same pattern of the glucose
uptake rate in methotrexate treated EAT cells by thymidine as
in in vivo study.
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Table 403 In vivo thymidine effect on glucose uptake and
cytochalasin B binding of methotrexate treated
EAT cells.a
Cytochalasin B Binding2-deoxy-D-glucose Uptake
BoKm KdVmaxGroups






a Each mouse was inoculated with 107 cells. 0.2 ml of
saline, MTX (l07 mg/kg), MTX (1.7 mg/kg) and
thymidine (20 mg/kg), thymidine (20 mg/kg) alone was
injected i.p. on days 2, 4 and 6 for control, MTX,
MTX+ thymidine and thymidine groups respectively.
Mice were sacrified on day 7. Cells were collected
by exhaustive drainage. 2-deoxy-D-glucose and
cytochalasin B binding were assayed as described
in the text.
Values are presented as mean + S.E.M. for triplicate
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determinations.
The level of significance was evaluated by Student's
t-test.
* p 0.01 when compared with control
** P 0001 when compared with MTX
***P Ool when compared with control
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Table 4.4 In vitro thymidine effect on glucose uptake
of methotrexate treated EAT cellsa
Groups Vmax Km
(nmol/min/106 cells) mM)
Control 18.78± 0.82 0.97± 0.06
MTX 15.89± 0.77 0.91± 0.08
MTX + Thymidine 20.31± 1.06 1.10± 0.07
Thymidine 21.24± 3.03 1.29± 0.24
a 5 x 105 EAT cells/ml were incubated with medium, 2 uM
MTX alone, 40 uM thymidine followed by addition of 2
uM MTX 2 hr later, 40 uM thymidine alone for control,
MTX, MTX+ thymidine, and thymidine groups
respectively. Cells were then washed with PBS after
24 hours and assayed for 2-deoxy-D-glucose uptake.
Values are presented as mean± S.E.M. for
triplicate determinations.
The level of significance was evaluated by Student's
t-test.
* P 0.05 when compared with control
** P 0.01 when compared with MTX
*** p 0.1 when compared with control
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THE EFFECT OF URIDINE ON MTX TREATED EAT CELLS
The effect of uridine on methotrexate was also studied.
Experimental protocol is exactly the same as the thymidine
rescue. The only change is the replacement of uridine for the
thymidine in the experiment. Table 4.5 shows the results of
tumor size in tumor bearing mice. Uridine either at the low
dose (20 mg/kg) or at the high dose (200 mg/kg) could not
exert any reverse effect on the tumor size of methotrexate
treated mice. The data even shows a synergistic effect of
uridine at high concentration (200 mg/kg) when administered
with methotrexate (P< O.Ol). Uridine alone, however, did not
show any reduction in tumor size (P >O.l).
Uridine does not show any ability to reverse the
inhibition of glucose uptake and reduction of glucose carriers
number by methotrexate in vivo (Table 4.6 and 4.7). 20 mg/kg
uridine could not relieve the 20% suppression of carrier
number by methotrexate (Fig. 4.7). The glucose uptake data do
not show any significant reversal effect either (Fig. 4.6).
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MTX+ Uridine (20 mg/kg) 3.51+ 2.49
1.18+ 0.93MTX+ Uridine (200 mg/kg)
Uridine (20 mg/kg) 15.62+ 4.80#
Uridine (200 mg/kg) 15.02+ 3.45#
Each group consisted of 10 mice. The mice were
7
inoculated with 10 cells on day 0.
0.2 ml of the drugs indicated in saline was injected
i.p. on days 2, 4 and 6 post-implantation. Saline was
injected for the control group. Tumor cells were
harvested and counted with haemocytometer on day 7.
Results are presented as mean± S.E.M.
b The level of significance was determined by Student's t-
test.
P< 0.001 when compared with control
# P >0.1 when compared with control
□ P< 0.01 when compared with MTX
+ P>0.1 when compared with MTX
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Table 406 The effect of uridine on glucose uptake of EAT




Control 23066+ 0074 1055+ 0.03
MTX 16.27+ 0.08 0.74+ 0.001
MTX+ Uridine (20 mg/kg) 17.61+ 0 73# 0.72+ 0.04
MTX+ Uridine (200 mg/kg) 16019+ 0 59# 1002+ 0.08
Uridine (20 mg/kg) 12.60+ 1.10 0.62+ 0.11
*
Uridine (200 mq/kq) 16.81+ 1.16 0.86+ 0.10
a The experimental details are as described in Table 4.3,
except that thymidine was substituted by uridine.
* P< 0.001 when compared with control.
# not significant when compared with MTX group
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Table 4.7 The effect of uridine on cytochalasin B binding
of EAT cells in methotrexate treated micea
Groups Bo Kd
pmol/l07 cells) (10-7 M)
142.54 ± 8.7Control 2.33 ± 0.17
116.96 ± 6.3*MTX 2.06 ± 0.19#
MTX + Uridine (20 mg/kg) 119.64 ± 6.2@ 1.79 ± 0.19#
151.85 ± 15.0#Uridine (20 mg/kg) 2.36 ± 0.53#
a Experimental details were as described in Table 4.3,
except that thymidine was substituted by uridine.
* P < 0.01 when compared with control
□ not significant when compared with MTX group
# not significant when compared with control group
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THE EFFECTS OF THYMIDINE AND URIDINE ON THE DNA, RNA AND
PROTEIN SYNTHESIS OF MTX TREATED EAT CELLS
The rate of DNA, RNA and protein synthesis in various
groups of treatment were estimated by radioactive thymidine,
uridine and leucine incorporation respectively. Table 4.8
shows that both three precursors exhibited significantly
higher incorporation rate in the MTX-treated EAT cells when
the mice were injected with thymidine concurrently. In
contrast, for the MTX+ uridine group, when compared with MTX
group, there were no changes in thymidine and leucine
incorporation and even significantly lower uridine
incorporation rate was observed.
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Table 4.8 The effects of thymidine and uridine on





MTX+ thymidine 171.59 ± 31.1* 126.60 ± 18.3** 161.43 ± 39.2*
MTX + uridine 99.11 ± 21.8# 84.33 ± 31.3# 82.04 ± 15.4*
a Experimental details are as described in Tables 4.1
and 4.5.
b Incorporation of precursors in EAT cells were
performed as described in Chapter 3.
MTX group is considered as 100%.
The significance of difference was determined by
Student's t-test.
* P < 0.01




Our results clearly demonstrate that thymidine can
significantly reverse the inhibitory effect of MTX on the
growth and viability of EAT cells in vivo (Fig. 4.5 and Table
4.1) and in vitro (Fig. 4.6). The mechanism of this partial
protection of tumor cells induced by thymidine is not clearly
understood. Hoglind-Semon and Grindey (1978) proposed that
external thymidine might modulate thymidylate synthetase
activity resulting in the sparing of already reduced pool of
tetrahydrofolate (FH4) in the cells. As shown in Fig. 4.2,
the synthesis of deoxythymidine-5'-monophosphate (dTMP) by
thymidylate synthetase involves the transfer of a one-carbon
unit from a FH4 cofactor to deoxyuridine monophosphate (dUMP)
and the resultant formation of dihydrofolate (FH 2 ).
Inhibition of dihydrofolate reductase by MTX thus interferes
with the reduction of FH2 back to FH4, producing a loss of
these FH 4 cofactors in the cello This depletion of FH4
cofactor would therefore occur in less frequency in cells
which contained lower thymidylate synthetase activity, since
this is the only reaction which converts FH4 to FH2. Upon
metabolic conversion to deoxythymidine-5'-triphosphate (dTTP),
thymidine may decrease the activity of thymidylate synthetase.
This decrease may be the consequence of feedback inhibition by
dTTP of the pathway of dUMP synthesis (Jackson, 1978),
resulting in a decrease in intracellular dUMP pools. This
hypothesis gains experimental support from the study of
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Grindey et al. (1979) that 5-fluorodeoxyuridine, which is a
potent inhibitor of thymidylate synthetase, can substantially
reduce MTX toxicity in mice when both agents were administered
by continuous infusion.
In preclinical and clinical studies, high dose of MTX can
be administered safely by prolonged infusion in experimental
animals (Hoglind-Semon and Grindey, 1978) and patients (Bruno,
1979) in the presence of thymidine. The molecular mechanism
for this reversal of toxicity to normal cells without losing
the anti-tumor activity of MTX is still not clearly defined.
Our results on EAT cells clearly indicate that there are at
least 20% decreases in anti-tumor activity of MTX when it is
co-administered with thymidine in vivo (Table 4.1) and in
vitro (Fig. 4.6A). To further evaluate the clinical
applicability of this concept, i.e. rescue the normal cells by
thymidine and at the same time retent the anti-tumor activity
of MTX, it is important to determine the relative ratio of the
dosage of MTX to that of thymidine so to provide maximum
therapeutic value of MTX to cancer cells.
Our results also indicate that administration of uridine
could not reverse the anti-tumor effect of MTX in vivo (Table
4o5). These results are consistent with the previous proposal
(Hoglind-Semon and Grindey, 1978). External uridine has no
salvage pathway to decrease the rate of thymidylate synthetase
so that the intracellular FH cofactors cannot be retained by
uridine administration. In contrast, excess uridine might
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drive the conversion of dUMP to thymidine through the step of
thymidylate synthetase and thus decrease the FH cofactors
pool. In this regard, it is also of interest to determine the
effect of purine on the reversal of MTX cytotoxicity on normal
and tumor cells. Since inosine and hypoxanthine can enter the
intacellular purine nucleotides pool through Salvage pathway,
their administration should restore the FH cofactors pool
in the cell, resulting in reversal of the cytoxic effect of
MTX.
Results in Table 4.3 and 4.4 indicate that thymidine
can also significantly reverse the inhibitory effect of MTX on
glucose uptake and glucose-sensitive cytochalasin B binding in
vivo and in vitro. Since the Km values of the uptake and Kd
values of the cytochalasin B binding remained relatively
unchanged, the alteration of the nature of the glucose carrier
after MTX treatment or MTX-thymidine treatment need not be
invoked. In our previous studies on the effect of MTX on the
glucose transport system of EAT cells, we (Chan et al, 1983)
found that the efficacy of MTX in reducing the glucose carrier
number roughly paralleled its efficacy in reducing tumor size.
These findings suggest that MTX-inducing depletion of
nucleotides and the consequent inhibition of DNA, RNA and
protein synthesis might have constituted primary chain of
events leading to reduced carrier production. Our data on
thymidine reversal of anti-tumor effect of MTX on EAT cells
confirm the above postulation. Thymidine can protect EAT
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cells to a certain degree from the cytotoxicity of MTX and at
the same time increases of glucose uptake and glucose carrier
density on EAT cells were oberved. Results in the precursors
incorporation of MTX+ thymidine group and MTX+ uridine group
(Table 4.8) further substantiated this view. Thymidine
administration to EAT-bearing mice could reverse the
cytotoxicity of MTX to tumor cells (Table 4.1). At the same
time, thymidine could also increase the precursors
incorporation rate of the MTX-treated cells (Table 4.8). In
contrast, uridine administration could not reverse the
cytotoxic effect of MTX on EAT cells (Table 4.5), and nc
significant increase of precursors incorporation could be
observed. It is worthy to note that changes in glucose uptake
and glucose carrier density was observed only in MTX-thymidine
treated group (Tables 4.3 and 4.4).
Our results also indicate that uridine alone can decrease
the glucose uptake to a significant level (P < 0.001) (Table
4.6). This is out of our expectation and may suggest that the
uridine effect is a complicated one and more other factors
have to be considered before we can draw a conclusive
explanation. In this correction, it is of interest to note
that some of purines, especially guanosine and inosine, have
been demonstrated to be hyper-repressors of glucose carrier in
chick-embryo fibroblasts (Gay and Amos, 1983). In this study,
it has also been shown that-thymidine has no effect on glucose
uptake where uridine had some effect on glucose uptake by this
cultured chick cells. The underlying mechanism of purines as
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hyper-repressor for glucose transporter in cells is still
unknown. However, it is reasonable to test the relationship
between the 'purineless' condition eliciting by MTX treatment
versus the glucose uptake mechanism of EAT cells. It has also
been reported by Gay and Amos (1983) that the rate of glucose
transport and the intracellular phosphoribosy1 diPhosPhate
(PPRibP) concentrations of chick-embryo fibroblasts are
inversely correlated. We do not know whether MTX can vary the
intracellular content of PPRibP and whether thymidine rescue
play any role on PPRibP. The measurement of PPRibP in the




EFFECTS OF INTERFERON INDUCERS ON TUMOR GROWTH AND GLUCOSE
TRANSPORT IN EHRLCH ASCITES TUMOR CELLS
INTRODUCTION
Interferon inducers are any initiating entities
responsible for interferon formation (Kleinschmidt, 1972).
There are a variety of agents capable of inducing interferon
production when given to the appropriate animals or in vitro
cell culture system. Among these are viruses, endotoxin,
bacterial extracts, double-stranded ribonucleic acids,
antigens, rickettsiae, viral nucleic acid, and a heterogeneous
group of synthetic compounds that range in molecular weight
from the polycarboxylates (MW 30,000) to some very low
molecular weight compounds like pyrimidinone interferon
inducers (MW 200) (Stringefellow, 1981).
INTERFERON AND ITS ANTITUMOR ACTION
Interferons are a group of inducible glycoproteins wnicn
are produced in response to, and act to prevent replication
of, an infecting virus within the invaded cells. Since the
discovery of interferon by Issacs and Lindenmann (1957), a
vast of researches have been focussed on this kind of cellular
n1wr-nnrntPin_ Interferon can be produced in cells both in
75
tissue culture and in the intact animal. However, the
classical source of interferon production are lymphoblastoild
cells of the reticuloendothelial system and peripheral blooi
leucocytes (Interferon a), and fibroblasts (Interferon B) a,
well. These two kinds of interferon belong to type
interferons which are pH2 stable and generally termed viral
interferons. The fact that there exist multiple molecular
species (types and subtypes) of interferon with different
biological functions has recently brought about the discover
of so called immune-type (type II) interferon y. This
molecular variant of interferon is in fact a lymphokine which
can be produced by sensitized lymphocytes with viable
Mycobacterium bovis, strain BCG or whole dead tubercle bacilli
etc. and challenged with specific antigen like old tuberculin,
or by exposure of nonsensitized lymphocytes to mitogens such
as phytohemagglutinin or concanavalin A (Neta Salvin, 1981).
This immune type interferon is speculated to have a more
potent antitumor potential than the classical interferons and
have synergistic antiviral as well as antitumor effects when
administered in combination with classical interferons
(Fleischman, Kleyn & Baron, 1980).
Certain biological and physiological properties of
interferon are briefly reported here:
(1) Interferon is species specific but lacks viral
specificity.
(2) Interferon is nondialyzable,nonsedimentable at 105,000g
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for 2 hr, is destroyed by proteolytic enzymes and it
posseses,isoelectric points pH 6.5-7.5.
(3) Interferon a and interferon B are stable at pH 2,
whereas interferon Vis pH 2 labile.
Although interferon Y was originally described and
characterized as a specific antiviral substance, it has also
been shown to affect normal cell division and function
(Gresser et al., 1970). In recent times, much of the interest
has been developed in the anticellular and particularly the
antitumor effects of interferon.
A vast literature has accumulated on the subject of
antitumor effect of interferon (Vignaux, Stanislawski and
Gresser, 1984 Roos, Leanderson Lundgren, ,1984; Billiau,
1981 Koi, Motoo, Ebina & Ishida, 1981; Trapman, 1979; Ryd et
al., 1979; Takeyama et al., 1978; Levy, 1970). In his review
of interferons as antitumor agents, Billiau (1981) raised at
least 3 possible mechanisms by which interferon may inhibit
tumor proliferation. They are:
(1) Inhibition of cell growth due to a reprogrammation of
cellular metabolism. At least two intracellular enzymes with
regulatory capacity for protein synthesis are induced by
interferon treatment of cells. Both enzymes, an
oligonucleotidyl synthetase and a protein kinase (Riviere &
Hovanessian, 1984 Hovanessian et al., 1977 Roberts et al.,
1976), originally synthesized in an apparently inactive form,
are activated by interferon. Furthermore, it has been found
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that interferon can inhibit tumor cell multiplication (Gresser
Tovey, 1978). Interferon appeared to block the entry of
tumor cells into the S phase during cell division (Roos,
Leanderson Lundgren, 1984 Richard, Panniers Clemens,
1981 Sokawa, Watanabe Kawade, 1977).
(2) Alteration in cellular surfaces (Knight Korant, 1977
Gresser Tovey, 1978 Friedman, 1981) may, for example,
diminish transport of nucleosides and thus impair the nucleic
acid synthesis in tumor cells. Interferon treatment also
results in enhanced expression of tumor-specific
transplantation antigens which are held to be a target for the
immune attack on tumor cells.
(3) Immunomodulation may cause stimulatory effect on the
efferent arm (antibody-dependent or purely cellular effector
mechanisms). Though interferon shows direct.effect on tumor
cell proliferation in vitro, the serum concentration in vivo
seems rather low compared to the dose of interferon needed for
tumor cell inhibition (Strander Einhorn, 1977). Thus, part
of the effect of interferon might be related to its potent
effects on the immune system. Evidences have shown that
antibody-dependent cell-mediated cytotoxicity (Herberman,
Ortaldo Bonnard, 1979 Heron et al., 1979) and cytotoxicity
of specifically sensitized T-cells are enhanced. Interferon
has also been shown to stimulate phagocytosis as well as
tumor-cell inhibitory effects of macrophages in culture
(Schultz, Papamatheakis Chirigos, 1977), enhanced natural
killer activity of unsensitized peripheral blood mononuclear
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cells (Gidlung et al., 1978). All these interferon-mediated
host reactions may account for the findings that interferon
treatment increased the survival of mice inoculated with
interferon-resistant L 1210 cells (Gresser, Maury Brouty-
Boye, 1972).
THE USE OF INTERFERON INDUCERS
The attraction, of interferon for use as an antiviral and
antitumor agent is based on its broad spectrum of actions. In
comparison with other drugs, interferon gives rise lesser
toxic effect and this effect is transient and has not produced
any long term detrimental changes.
Clinical trials of interferon has had the problem of
variability in preparations available. In addition, accepted
methods for quantitating interferon preparation have limited
to biological assays which have greater variability. The
problem of purity is another difficulty in evaluating the
efficacy of interferon preparations used today. Whether or not
completely pure material will have identical properties to
those less pure preparations commonly used remains unknown.
Batch to batch reproducibility is hence a problem in
evaluating the efficacy of interferon preparations in research
study. Another problem confronting interferon study is the
sufficient quantity of interferon preparations available.
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Though the recent recombinant DNA technique is promising for a
higher yield of interferon production, the current quantities
of interferon preparations have not been sufficient for the
experiments.
Interferon is produced by leucocytes, fibroblasts and
kinds of inducers, ranging from viral vaccines to synthetic
compounds and naturally occurring substances, have been found
to exhibit antitumor effects (Wheelock Dingle, 1964
Kleinschmidt et al., 1964 Field et al., 1967 Levy et al.,
1969 Krueger Mayer, 1970). These inducers also produced in
tumor-bearing hosts proteins which have been characterized as
interferons by identical properties to the interferons
produced in vitro (Lvovsky et al., 1977). Though some
(Weinstein et a1., 1971) refused the correlation of antitumor
effects of inducers and endogenous interferon, several
investigators concluded that the antitumor effects of inducers
were mediated by interferon (Sarma et al., 1969 Gresser et
al., 1969a Gresser and Bourali, 1969 De Clercq, 1977
Riviere et al., 1977). These inducers can also exert
antitumor action with apparent phenomena similar to interferon
action. For example, polyl:C can also enhance the cell-
mediated immune response and direct action on tumor cell (Rhim
Huebner, 1971 Gresser et al., 1978). Enhanced natural
killer activity (Gidlung et al., 1978) and macrophage
activation (Schultz et al., 1977)was observed in mice injected
with interferon inducers.
immune system in response to cettain inducers. Certain such
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Though the administration of interferon inducers may
cause worries of toxicity and side effects and also the
problem of hyporesponsive state development, ie. a reduced
interferon response to repeated doses of inducers (for review
see Pollard, 1982), inducers hold the advantages of readily
available in commercial forms, experimental results
comparable, antitumor effects other than interferon action and
higher degree of purity can be obtained. Experiments have
been devised to minimize the toxicity of inducers and to
explore the existence of other inducers with minor toxic
effects. The hyporeactive state can be overcome by allowing
longer intervals between successive injections of the inducers
or by alternating injections of different interferon inducers
(De Clercq, 1981). Since there are various types of
interferon with different biological and therapeutic
properties, the administration of interferon inducers may
sometimes be advantageous over treatment with interferon when
the type of interferon used may not necessarily be the one
which interacts with tumor cells.
INTRODUCTORY REMARKS ON THE INTERFERON INDUCERS EMPLOYED IN
THE EXPERIMENTS
The interferon inducers we employed in the experiment are
synthetic compounds which have received much attention in
interferon study (Levy, 1970 Levy et al., 1970 Talal, 1971
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Rhim Huebner, 1971 Kleinschmidt, 1972 duBuy, 1972 Schultz
et al., 1977 Lvovsky et al., 1977 Gresser et al., 1978
Gidlung et al., 1978 Trapman, 1979 DeClercq, 1981 Pollard,
1982 Nagano Takano, 1982). The nomenclature and structural
features are shown in Table 5.1.
The first one is a synthetic double-stranded RNA,
polyinosinic-polycytidylic acid (Poly I:C). It has been most
widely used as an interferon inducer because of its relatively
low toxicity and favourable inducing properties. When
administered to animals or introduced into cell cultures it
exhibits a broad biological effects including the induction of
interferon, an interference with the growth of several
experimental malignant tumors, an adjuvant-like potentiation
of cellular and humoral immune response, and the provocation
of antibodies specific for double-stranded RNA (Talal, 1971).
Poly I:C was discovered by Hilleman and his co-workers (1967)
during their search for a potent interferon inducer. The
compound is made by annealing the homopolymer polyinosinic
acid with the complementary polycytidylic acid. It is one of
over twenty double-stranded RNAs that have been shown to
induce interferon. There has been considerable experimental
evidence showing that double-stranded polyribopolymers are
more active than synthetic or natural single-stranded polymer,
and that DNA is much less active than RNA in interferon
induction (Kleinschmidt, 1972). This has led to the
postulation of a specific intracellular receptor, perhaps a
protein, that recognizes specific biochemical features of the
82
Table 5.1 The nomenclature and structural features of
the interferon inducers we employed in the
experiments.






analog of diamine c,d,e
analog RlO,024DA 2, 7-bis-(2-diethylamino-
ethoxy)-fluoren-9-one
statalon











a. Levy et al., 1970
b. Talal, 1971
c. Kleinschmidt, 1972
d. Meindi, Bodo & Tuppy, 1976
e. Stringfellow, 1981
f. Kleinschmidt, Cline & Murphy, 1964
g. Lvovsky et al., 1977
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inducer (Colby Duesberg, 1969).
For the antitumor action of Poly I:C, a list of animal
tumors were found sensitive to Poly I:C treatment (Table 5.2,
from Levy et al., 1970). The mechanism of action of Poly I:C
seems to be a combination of:
(a) The mediation of interferon induced in the host. Gresser
et al. (1978) have found that the use of anti-interferon
globulin could nullify the anti-tumor effect of Poly I:C.
Although they could not rule out the possibilty that the
loss of anti-tumor effect might be by a mechanism other
than the neutralization of endogenous interferon.
Declercq (1977) suggested that the endogenous interferon
was important to render the tumor cells sensitive to the
cytotoxic effects of Poly I:C.
(b) Direct chemotherapeutic effect of Poly I:C, perhaps
through integration into biosynthetic processes occuring
in the tumor. Studies have shown that mice bearing a
reticulum cell sarcoma showed inhibition of protein and
RNA synthesis by the tumor 16 hours after the
administration of Poly I:C. By contrast, normal tissues
in these mice showed either enhanced or minimally altered
synthesis (Levy, 1970).
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Table 5.2. Effect of Poly I:C on some animal tumors.
Treatment, in most cases, was 150-200 ug/mouse





J96132-Reticulum cell sarcoma( c.)
96 b
J96132-Reticulum cell sarcoma (ascites)
100Carcinosarcoma Walker 256













a Data are obtained from review by Levy et al., 1970.
With the exception of the animal with J96132 with
reticulum cell sarcoma, some with Ehrlich ascites tumors,
and a few with Walker carcinosarcoma, all animals
ultimately died.
b Data are presented in mean day of death of the animals
that died. It is reported that about 30% of all the
animals treated have survived, although treatment had
been stopped at about day 50.
c.= subcutaneous injection
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(c) The enhancement of cell mediated defense mechanisms
against foreign antigens, for example, enhancement of
graft-versus-host (GVH) reactions, suggests that Poly
I:C can through the enhancement of cellular immunity
and contribute to the rejection of malignant tumors by
immunologic means.
The second inducer is tilorone, which belongs to a group
of low molecular weight interferon inducers. Since they are
small in size, they can be cleared rapidly from the animal and
are not antigenic (Stringfellow, 1981). However, some of them
have undesirable toxicity and researches are developed to
decrease their toxicity and improve their therapeutic activity
in experimental animal. Tilorone has been shown to alter the
expression of delayed-type hypersensitivity responses
(Kettman, 1978) and induce lymphokines production (Neta,
1981). In vivo tilorone can increase natural killer cell
activity and exert antitumor effect (Gidlung et al., 1978).
The increased macrophages induced by tilorone treatment also
accounts for the enhanced resistance to acute infection with
Trypanosoma cruzi in mice (James et al., 1981). However,
tilorone are incapable to induce interferon in vitro. This
suggests that tilorone, like endotoxin, may not cause de novo
synthesis of interferon, but may cause release of preformed
interferon (Kleinschmidt, 1972).
The third inducer is statolon, a fermentation product of
Penicillium stoloniferum (Kleinschmidt, 1972). This material
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was identified initially as an anionic polysaccharideo Closer
examination by Kleinschmidt and Ellis by sucrose gradient
centrifugation of statolon showed that the activity was not
associated with a polysaccharide but with a virus derived from
the mycelia of P. stoloniferum. The experiment using anti-
interferon globulin (Gresser et al., 1978) showed that the
antitumor activity of statolon was mediated by interferon
induced.
The last interferon inducer we used in our laboratory is
S,2-aminoethylisothiouronium hydrobromide (AET). An
interferon-like substance and virus-resistant state in the
mouse was found with the treatment employing AETQ Since it is
radioprotective, it is active orally and diffuses through
membrane carriers such as central nervous system.
Pharmacological studies in man indicate that AET and related
compounds can be administered with relative safety (Lvovsky et
al., 1977).
THE EFFECTS OF INTERFERON INDUCERS ON EHRLICH ASCITES TUMOR CELLS
The antitumor effects of interferon and interferon
inducers have been studied by many investigators (Gresser,
1972 Field et al., 1967 Krueger Mayer, 1970 Levy et al.,
1969). In their treatments of Ehrlich ascites tumor-bearing
mice with interferon preparation, Gresser and Bourali (1970)
found that:
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1) Interferon treatment of mice before inoculation of tumor
cells was ineffective.
2) Subcutaneous administration of interferon increased mouse
survival, but was probably less effective than i.p.
injection.
3) The efficacy of treatment in increasing mouse survival was
directly proportional to the number of tumor cells
inoculated.
4) Phagocytosis of tumor cells by macrophages was observed on
smears obtained from the peritoneal cavities of mice
treated with interferon, but not from control mice.
5) Interferon-treated mice surviving inoculation of tumor
cells had an enhanced resistance to reinoculation of tumor
cells.
DuBuy (1972) used Poly I:C in treating Ehrlich ascites
tumor carrying mice and obtained similar results. The mice
with tumor cells inoculated intraperitoneally survived
significantly longer when given Poly I:C treatment i.p., as
compared with subcutaneous treatment. The findings suggest
that the more contact of the cancer cells with Poly I:C, the
more effective the treatment. Nagano and Takano (1982) used
similarly Poly I:C against EAT cells and measured significant
levels of interferon in mouse serum after Poly I:C treatment.
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AIM OF STUDY
In our laboratory, we measured the efficacy of interferon
inducers, namely, Poly I:C, statolon, tilorone and AET in
treating Ehrlich ascites tumor. Since reports concerning the
effect of interferon or interferon inducers on the glucose
transport system of cancer cells are lacking, we also examined
the effects of these interferon inducers on glucose transport
process of EAT cells. Because the effect of Poly I:C on tumor
cells have been examined more in literature, its action on
Ehrlich ascites tumor cells will also be investigated in




PREPARATION OF DRUG SOLUTION
Poly I:C was dissolved in distilled water at 10 mg/ml and
stored in freezer. It was diluted in phosphate-buffered
saline, pH 7.4 (PBS) to desired concentration before use
(Nagano Takano, 1982). Statolone, tilorone and S,2-
aminoethylisothiouronium hydrobromide (AET) were dissolved or
suspended in PBS and stored in freezer. Poly I:C and statolon
required sonication to aid their solubilities in PBS.
TREATMENT OF TUMOR BEARING MICE
Male mice weighing 30-35 g were inoculated i.p. with 107
Ehrlich ascites tumor cells harvested from 7-day old tumor on
day 0 in 0.2 ml PBS. All groups consisted of at least 10
mice. The drug administration was carried out on days 2, 4
and 6 unless specifically stated. The control group received
only PBS. On day 7, the mice were sacrified by bleeding from
the subclavian vessels or by cervical dislocation. Sera was
collected by centrifugation and stored in freezer till use.
Tumor cells were collected by exhaustive drainage. Pooled
cells were washed 5 times with half-isotonic saline to remove
blood cells and resuspended in PBS and the viability of the
cells was determined by trypan blue exclusion to ensure
viability higher than 95% in all cases. For glucose uptake
and cytochalasin B binding experiment, the cells were
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resuspended to 2 x 10 /ml. For the interferon assay, the
sera were serially diluted and added to the wells containing
L929 cells of a micro-titer plate. After the overnight
incubation, the cells were challenged with vesicular
stomatitis virus and the results were read after 24 hours of
incubation.
For the test of serum factor which may affect the tumor
cells, sera obtained from Poly I:C treated mice and control
mice were injected daily to new groups of tumor-bearing mice.
On day 7, the mice were sacrified. The tumor cells were
harvested, washed and resuspended to the concentration for the
glucose uptake and cytochalasin B binding.
For the effect of Poly I:C pre-treatment on the tumor
cells, 300 ug of Poly I:C was injected intravenously to the
mice every 2 days starting 2 weeks before the inoculation of
tumor cells. After the tumor cells inoculation, the mice
received no further Poly I:C treatment. The results were used
to compare with those of control group which received PBS
only, and another group which received same dose of Poly I:C
only on days 2, 4 and 6 after tumor cell inoculation.
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RESULTS
Since different ways of interferon inducers
administration may play a significant role in tumor
regression, in a pilot study we examined the most effective
route of administration of poly I:C and statolon because no
information is available for these two agents. Table 5.3
shows that subcutaneous injection of poly I:C and statolon
seem to have the least efficiency in suppressing tumor growth.
Intravenous injection of poly I:C is effective, but the most
effective way is by intraperitoneal injection. Subcutaneous
injection of statolon gave rise the least antitumor effect
whereas subcutaneous injection of poly I:C still held certain
antitumor power (30%)o In the following experiments, both
poly I:C and statolon were injected to mice intraperitoneally.
since Poly I:C received much of attention in interferon
induction because of its lesser toxicity and greater capacity
of producing interferon, its effect on EAT were examined.
Fig. 5.1 shows the effect of different doses of Poly I:C
on tumor size. Poly I:C was effective in suppressing EAT
growth and the effect was in a dose-dependent manner.
When the effects of different doses of Poly I:C on the
glucose transport properties were examined (Table 5.4), it was
found that the glucose-sensitive cytochalasin B binding (Bo)
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shows a significant decrease (P <0.01) when 75 to 450 ug
poly I:C were injected to each mouse. However, there was only
a general reduction in glucose-sensitive binding sites and it
did not show any significant dose response manner. Moreover,
the kd values of the binding of cytochalasin B to EAT cells
remained relatively unchanged in different poly I:C dosages.
As shown in Fig. 5.1, dosage of 300 ug/mouse could
exhibit maximal suppression of EAT growth, we chose this
dosage for the test of poly I:C in the following experiments.
An experiment on this suggested dose of poly I:C showed that
the tumor size was reduced up to 40% (P< 0.001).
Administration of poly I:C could decrease both the maximal
uptake rate (Vmax) and glucose-sensitive cytochalasin B
binding by nearly 20% (P <0.001). However the Km and Kd
values showed no significant change (Table 5.5).
Concerning interferon titer, there was no interferon in
the sera of control mice while detectable interferon titer
(16+ 8 units/ml), though relatively low, was observed in the
sera of poly I:C treated mice (Table 5.5).
To test that if any antitumor effects occur in the sera
of poly I:C treated mice, such sera was injected to EAT
bearing mice on days 2, 4, 6 and cells were counted on day 7.
Table 5.6 shows that when poly I:C treated mice sera
(containing 16± 8 units/ml of interferon titer) were injected
to mice the tumor growth was significantly suppressed as
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Table 5.3 The effects of different routes of administration
of Poly I:C and statolon on tumor size of EAT
a
cells.
Tumor Size(% of Control)Groups
42.12+ 14.90Poly I:C i.p.
47.72+ 21.93Poly I:C i.v.
*





a Each group consisted of 10 mice.
300 ug/moue in 0.2 ml PBS of poly I:C and 5 mg/mouse in
0.5 ml PBS of statolon was administered to the test
groups on days 2, 4 and 6 after the inoculation of 107
cells on day 0. The mice were sacrified on day 7 and
the cells counted according to the text.








Fig. 5.1 Dose-response curve of different doses of
poly I:C on EAT tumor size.
Each group consisted of 10 mice. Each mouse
7
was inoculated with 10 cells on day 0. On
days 2, 4 and 6, the mice received i.p.
injection of indicated doses of poly I:C. The
control group received PBS.
On day 7, the mice were sacrified and the cell
were collected for cell count. The values












0 75 150 225 300 375 450
Doses of Poly I:C (ug/mouse)
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Table 5.4 The different doses of poly I:C on glucose-
sensitive cytochalasin B binding of EAT cells
in vivo.









a. Each mouse was inoculated with 10 cells on day 0.
0.2 ml of PBS and the indicated doses of poly I:C
was injected i.p. on days 2, 4 and 6 to the control
and the Poly I:C groups respectively. Mice were
sacrified on day 7. Cells were collected and
assayed for glucose-sensitive cytochalasin B
binding as described in Chapter 3.
Values are represented as mean+ S.E.M. of 3
experiments.
* P 0.01 when compared with control group
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Table 5.5 In vivo effects of Poly I:C on the tumor size
and glucose transport properties of EAT cells
a
and serum interferon titer induced.
Groups Tumor size Interferon Titer
(10 8/mouse)
(reference unit/ml serum)
Control 17.9+ 2.4 2
Poly I:C 10.64+ 2.6 16+ 8
2-deoxy-D-glucose uptake Cytochalasin B binding
BoKmVmax KdGroups
(nmol/min/106 cells) (mm) (pmol/107 cells) (107-/M)
1.8+0.04123.4+1.51.30+0.0326.11+0.50Control
1.7+0.12101.3+3.31.21+0.0319.39+0.49Poly I:C
Each group consisted of 10 mice. The mice were inoculated
with 107 cells on day 0. The Poly I:C group received 300
ug/mouse Poly I:C i.p. injections on days 2, 4 and 6. The
control group received only PBS. The mice were bled on day
7 for interferon assay. The mice were then sacrified and
cells were harvested and tumor size measured by
hemacytometer. Cells were also pooled and assayed for
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glucose uptake and cytochalasin B binding. The serum
interferon assay and the glucose transport were determined
as described in Chapter 3.
The results are presented as mean+ S.E.M. of 2 experiments,





Table 5.6 The effect of poly I:C serum on tumor size and
glucose transport activity of EAT cells and the
serum interferon titer in vivoa
Groups Tumor size Interferon assay
(108 cells/mouse) (reference unit/ml serum)
Control Serum 13.54+ 4.20
8.26+ 3.67Poly I:C Serum
Cytochalasin B binding2-deoxy-D-glucose uptake
Vmax Bo KdKmGroups





a Each group consisted of 10 mice.
Each mouse was inoculated with 107 cells. 0.2 ml of
control serum and Poly I:C serum was injected i.p. on




groups respectively. The mice were sacrified on day
7. The cells were collected, washed and assayed for
the glucose uptake and cytochalasin B binding as
described in Chapter 3.
b The original interferon titer present in the control
mice serum is < 2 and 16+ 8 units/ml in the Poly
I:C-treated mice serum. On day 7, serum from
individual mouse was collected and assayed the
interferon titer as described in Chapter 3.
Values are expressed as mean+ S.E.M. of 2
experiments.
P < 0.05 when compared with control serum group
# P> 0.2 when compared with control serum group
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compared to that of mice receiving control sera only.
However, when the interferon was assayed on day 7, titer of2
was observed in treated group. This might reflect the
relatively short half-life of interferon. When the glucose
uptake and glucose carrier were examined, no significant
change could be observed in the treated group as compared with
control group.
The antitumor effect of Poly I:C was compared with other
interferon inducers (Table 5.7). Except AET, all three
inducers showed a significant antitumor effect. About 30-50%
suppression of tumor growth was observed (P <0.001). Of these
interferon inducers, statolon seems to have greatest effect in
suppressing tumor growth. The effect of Poly I:C is similar
to that of tilorone. AET shows very little if any antitumor
effect (P >0.05) in reducing the tumor size. It should be
noted that both statolon and tilorone are two interferon
inducers which no interferon titer could be observed in some
mice. Concerning the glucose transport activity, decreases
in both uptake rate and carrier number when EAT cells were
treated with statolon, tilorone and poly I:C (Table 5.8). AET
has no effect in affecting the glucose transport activity and
glucose carrier density (P> 0.05 in both cases). There is no
great difference among tiorone, statolon and poly I:C under
test in affecting the values of Vmax and Bo.
Pretreatment of Poly I:C (Table 5.9) gave a significant
antitumor effect (p< 0.02) compared with control group though
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the effect is less than that of the Poly I:C treatment during
the course of tumor development in the host. The glucose
uptake and glucose-sensitive cytochalasin B binding of both
groups show a 35% decrease (P 0.05) compared with control
group. The Km and Kd values of both groups did not differ
significantly from the control.
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Table 5.7 The effects of different interferon inducers
on tumor size of EAT cells and serum
interferon titer in tumor-bearing mice.a
Groups Tumor size 0Interferon titer
(% of Control) (reference unit/ml serum)
Poly I:C 64.46+ 19.56 8+ 4
47.34+ 17.11 4+ 4Statolon
4+ 4Tilorone 70.17+ 22.23
85.43+ 22.27 < 2AET
a Each group consisted of 10 mice.
Each mice was inoculated with 107 cells on day 0. On
days 2, 4 and 6, the mice were administered with the
interferon inducers (Poly I:C, 300 ug/mouse in PBS,
i.p. statolon, 5 mg/mouse in PBS, i.p.; tilorone, 4
mg/mouse in PBS, oral AET, 4.5 mg/mouse in PBS,
i.p.). Mice were sacrified on day 7 and the cells were
counted by trypan blue exclusion method.
b The interferon assay was performed as described in
Chapter 3.





Table 5.8 The effects of different interferon inducers
on glucose transport activity of EAT cells in
vivo. a
2-deoxy-D-glucose uptake Cycocnaiasin B tinging
Groups Vmax Km Bo Kd
(pmol/107 cells) (10-7 M)(nmol/min/106 cells) (mM)
Control 21.09+1.90 D.86+0.06 117.2+2.6 1.82+0.06
Poly I:C 19.00+0.66 0.61+0.05 110.1+0.9 1.85+0.02
0.86±0.25 102.2+5.2 1.82+0.15Statolon 18.57+1.95
0.67+0.02 105.0+2.3 2.09+0.1316.89+0.02Tilorone
0.66+0.29 113.8+13.0 1.82+0.3817.04+3.86#AET
a The procedure for drug administration and the harvest of
tumor cells is the same as described in the legend in
Table 5.7. The cells were collected and assayed for the
glucose transport experiment as previously described.
The significance of difference between test and control
group was determined by Student's t-test.
* P < 0.05
# not significant
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Table 5.9 The effects of pretreatment with Poly I:C
(i.v.), and treatment of Poly I:C (i.p.)
during the development of tumor cells on
EAT cells.a







2-deoxy-D-glucose uptake Cytochalasin B binding
Groups Vmax Km Bo Kd
(nmol/min/106 cells) (mM) (pmol/107 cells) (10-7 M)
control 38.94+8.8 1.24+8.8
190.84+2.4 2.85+0.06
poly I:C 25.43+2.8 1.13+0.3 127.31+3.4 2.15+0.16
(i.P.)
pretreatment 24.60+2.8 0.94+0.2 125.15+6.7 2.72+0.04
of poly I:C
(i.v.)
a Each group consisted of 10 mice
108
The mice were inoculated with 107 EAT cells on day 00
For pretreatment of Poly I:C (i.v.):
The mice were injected with 300 ug/mouse Poly I:C
on alternating days started 2 weeks before the
inoculation of tumor cells. Then the mice
received no further injection during the
development of tumor.
For Poly I:C (i.p.):
The mice were injected i.p. with Poly I:C (300
ug/mouse) on days 2, 4 and 6.
The mice were sacrified on day 7. The EAT cells were
collected and ready for cell count, determinations of
glucose uptake and cytochalasin B binding.




*** P< 0.001 when compared with control group.
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DISCUSSION
The results we obtained are in accordance with the
results from the experiments by Gresser et al. (1978) as well
as Nagano Takano (1982). Poly I:C, statolon and tilorone
were found effective against Ehrlich ascites tumor cells
(Tables 5.4, 505, 507 and 5.8). AET, however, did not show
any significant antitumor activity. It is difficult to say
whether the antitumor effect of interferon inducers are
mediated by interferon. It would appear that, not
surprisingly, the inducers cause the formation of other
substances in addition to interferon, which lead to
suppression of tumor cells. With regard to immune system,
interferon inducers, especially in the case of poly I:C, have
been found to be stimulatory in anti-body production and cell-
mediated immunity, while the effects of interferon seem to
have been inhibitory (review see Levy and Riley, 1983).
Furthermore, poly I:C, tilorone and statolon can enhance
macrophage activity (James et al., 1981, Levy Riley, 1983)
and natural killer cell activity (Gidlung et al., 1978 Levy
Riley, 1983). Macrophages have been implicated in host
defenses against tumor (Levy Weelock, 1974). Natural killer
cells are a subpopulation of lymphocytes that can lyse a wide
variety of tumor cells. Interferon inducers should at least
exert some of their interactions on tumor cells through the
manipulation of immune system. However, our results indicate
that interferons are an important factor for suppressing
tumor growth in treated mice. For example, S,2-
aminoethylisothiouronium hydrobromide (AET) which produced
very low interferon titer in mice (Table 5.7) could not
suppress tumor growth. Furthermore, interferon-containing
sera (with interferon titer 16+ 8 units/ml) obtaining from
poly I:C-treated mice sera (Table 5.6) could significantly
suppress tumor proliferation.
In connection with the question of whether the tumor
suppression brought about by the inducers is attributable
solely to the interferon induced, it is important to note that
the interferon titer in sera are relatively low in mice
treated with poly I:C, statolon and tilorone (Table 5.7). In
many cases, no interferon could be found in the sera. It has
been reported that when an inducer is given to an animal,
maximum levels of interferon are produced after several hours
and decay of interferon is followed (Levy Riley, 1983).
Since the time we collected sera for interferon assay was 24
hrs after the last inducer injection, it is reasonable to
believe that low interferon titer might be the result of its
degradation. In this respect, it is also of interest to note
the findings by Matsubara et al., (1980) that there is a low
molecular weight fraction of cell-free ascitic fluid which
specifically impairs the induction of interferon in Ehrlich
ascites tumor-bearing mice. Our results on pre-treatment of
poly I:C on tumor-bearing mice reveal another example which
indicates interferon might be the only candidate for tumor
growth inhibition. Mice were pre-treated with poly I:C for 2
weeks before tumor inoculation and the growth of tumor was
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monitored 1 week later. Since no inducer nor interferon might
be present during tumor development, the observation that
suppression of tumor occured in this pre-treatment group
(Table 509) can only be explained by the postulation that
poly I:C might produce some long-acting antitumor agent(s) or
poly I:C might elicit the activation of immune system to
counteract the tumor cells.
We also showed that poly I:C, statolon and tilorone could
suppress glucose. uptake and glucose carrier density of
Ehrlich ascites tumor cells without changing the Km of uptake
and Kd values of the binding (Table 5.8). It is equally
difficult to know whether these decreases of glucose transport
process are mediated through interferon. Since reports about
the effect of interferon on glucose transport are lacking, we
do not know whether interferon itself can affect glucose
transport system in tumor cells. Furthermore, the possibility
of indirect action of the four inducers cannot be ruled out.
Treatment of poly I:C prior tumor inoculation could also
suppress glucose transport of Ehrlich ascites tumor cells in a
comparable degree as that of post-inocualtion treatment (Table
5.9).
Recently, Machida et al. (1984) found that blood
interferon samples obtained after injection of poly I:C in
mice might contain a and B interferons. In our experiments,
we administered poly I:C and other inducers to mice on
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alternate days (i.e. on days 2, 4 and 6 after tumor cells were
inoculated on day 0). We do not know which kind of
interferons might be produced in vivo. To investigate whether
interferons have any direct effect on glucose transport
system of tumor cells, it is important to obtain pure




EFFECT OF TUMOR NECROSIS SERUM ON THE GLUCOSE TRANSPORT OF
L929 CELLS
INTRODUCTION
Tumor necrosis factor (TNF) belongs to a group of
macrophage products with antitumor properties (Matthews, 1983)
using in vitro assays. These products include arginase
(Currie, 1978), cytolytic factor (Adams et al., 1980), tumor
necrosis factor (Matthews, 1978, 1981a), human monocyte
cytotoxin (Matthews, 1981b) and cytostatic factors CFI and
CFII from human monocytes (Nissen-Meyer Hammerstrom, 1982).
These factors may act separately or in concert for the
antitumor activities (Nissen-Meyer and Hammerstrom, 1982
Matthews, 1983).
Tumor necrosis factor was first described by Carswell et
al. as a substance in the plasma of animals with an endotoxin
shock induced by i.v. injections of Bacillus Calmette-Guerin
(BCG) and endotoxin 2 weeks apart. Tumor necrosis factor
containing plasma was found to induce necrosis of some
transplantable animal tumors in vivo (Carswell et al., 1975)
and to be cytotoxic to certain cell lines but not normal cells
in vitro (Carswell et al., 1975 Matthews Watkins, 1978).
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PRODUCTION AND CHARACTERIZATION OF TNF
Tumor necrosis factor can be produced either in vivo or
in culture. For in vivo production of TNF, a priming agent
has to be injected into the animal. The commonly used priming
agents include BCG, yeast cell wall (zymosan), Corynebacterium
parvum (C. parvum) (Green et al., 1977), plasmodia (Clark et
al., 1981), Mycobacterium lepraemurium (MLM) (Ha et al., 1983)
and Listeria monocytogenes (LM) (Ha et al., 1985). They share
a number of biological activities, such as increasing
resistance to bacterial infection and to certain experimental
tumors, inducing macrophage activation and proliferation,
altering cellular and humoral immune reactivity, and causing
heightened susceptibility to endotoxin lethality (Green et
al., 1977). The time of priming varies with different animals
but usually is within two weeks. After priming, TNF is
detected only after enough eliciting agent such as
lipopolysaccharide (LPS) which is usually used, or Pseudomonas
(Kiger, Khalil and Mathe, 1980) is given to cause death of the
animal. Mouse TNF is a glycoprotein. The moeity of lipid A
in LPS was found essential to TNF production while the
polysaccharide portion may be involved only in delivery the
lipid A moiety to TNF production cells (Ha et al., 1985). The
period of time for eliciting the release of TNF is between 45
min to 2 hr. The discovery that macrophage activation 2 days
after C. parvum administration and the production of TNF when
macrophage containing tissues from BCG-infected mice were
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incubated with LPS for 2 hr in vitro suggest the source of TNF
being macrophages (Green et al., 1977). Moreover, pyknosis
and disruption of macrophages in the greatly enlarged spleens
of the mice treated with BCG followed by endotoxin and the
concomitant outpouring of intracellular enzymes of lysosomal,
cytosolic, and microsomal origin indicates that extensive
cellular lysis occurs in the primed mouse treated with
endotoxino One example of this intracellular enzyme is NADase
which is an enzyme normally bound to the membranes, is found
in the serum of BCG mice after treatment with endotoxin (Green
et al., 1976)0 The lack of LPS dose-response effect in
eliciting TNF implies that LPS acts in a trigger mode rather
than as a primary stimulus on properly activated macrophages
(Mannel, Moore Mergenhagen, 1980).
Mouse. TNF has been partially purified by Green et al.
(1976, 1982) and Kull Cuatrecasas (1981). Rabbit TNF is
also purified to about 1000 fold by affinity chromatography
(Ruff Gifford, 1980). Recently, human recombinant tumor
necrosis factor has been obtained by expression of cDNA in
Escherichia coli (Pennica et al., 1984) and the protein thus
synthesized has the immunological characteristics as well as
in vitro and in vivo biological properties of natural human
TNF.
The effect of TNF can be assayed by necrotic response of
BALB/c sarcoma Meth A in vivo or L929 cells in vitro (Carswell
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et al., 1975). Recently, the cytotoxic activity of TNF has
been reproducibly detected through a 1/1,000 dilution by
measuring release of 3[ H]-thymidine from prelabeled target
cells (Manuel, Meltzer Mergenhagen, 1980) and through the
ability of survivor cells to incorporate the dye neutral red
to measure the effect to dilutions as great as 1/64,000 with
accuracy of+ 6% (Kull Cuatrecasas, 1981).
Biochemical characterization has shown that mouse TNF
protein exists in at least two forms with two different
molecular weight: 15,000 (Kull Cuatrecasas, 1981 Green et
al., 1976, 1982) and a 40,000-60,000 form (Mannel et al.,
1980 Kull Cuatrecasas, 1981). They migrate
electrophoretically in the a- globulin region. They are
0
stable at pH 6-11, 56 C but inactivate at 700C0 Green et al.
(1976) suggested mouse TNF was a glycoprotein because of the
presence of sialic acid and galactosamine moiety. Rabbit TNF
has a molecular weight of 39,000 (Matthews et al., 1980) to
67,000 (Ruff Gifford, 1980) and have similar physicochemical
properties as mouse TNF. The recently synthesized human
recombinant TNF is a polypeptide related structurally to
lymphotoxin. It has a relative molecular mass of 17,000 and
is not a glycoprotein. Human TNF may occur naturally in
multi-meric form. There are two cysteine residues in human
TNF which are probably involved in a single intramolecular
disulphide bond (Pennica et al., 1984).
DISTINCT TNF ACTIVITY FROM INTERFERON OR LYMPHOTOXIN ACTIVITY
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Tumor necrosis serum (TNS) may contain interferon and
migration inhibition factor other than TNF. Interferons, in
addition to their anti-viral effects, can also exhibit anti-
tumor effects (Gresser, 1977). Rabbit TNF and interferon have
certain properties in common: (a) similar physicochemical
characteristics, (b) production in vivo after challenge with
endotoxin, (c) release from mononuclear phagocytes in vitro
after short incubation periods at 37°C but not at 4°C nor on
cell disruption (Matthews, 1978).
However, TNS activities appears distinct from interferon
activities on the following bases (Matthews, 1979):
(a) TNF can be separated from the type I interferon of TNF
serum by passage through a Cibracon Blue-agarose.
(b) Preparation of Type I interferon induced by Poly I:C or
virus lacked TNF activity.
(c) Rabbit TNF has certain anti-tumor activity against human,
mouse and rabbit tumor cell lines, whereas the effect of
interferon is species-specific.
(d) Type I interferon has been renatured after boiling in
sodium dodecylsulfate and 2-mercaptoethanol, whereas the
denaturation of TNF is persistent (Kull Cuatrecasas,
1981a).
(e) Phentolamine can effectively inhibit interferon induction
but cannot antagonize the induction of tumor growth
inhibition by endotoxin (Bloksma et al., 1982).
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(f) The acid lability and heat stability of the TNS cytotoxin
resembled the characteristics of type II interferon
however, the preparation of TNS resembled the protocol
used to enrich serum for type I rather than type II
interfeon (Kull& Cuatrecasas, 1981a).
In view of the heterogeneous nature of interferon, it is
possible that the TNF and interferon activities share some
structure-function relationship. Further comparison must
await structural elucidation of both substances.
Both the TNF and lymphotoxin share certain mechanistic
similarities. Target cell killing by lymphotoxin is species
independent, requires prolonged exposures, and is enhanced by
inhibitors of protein synthesis. Stimulation of RNA synthesis
is reported for both TNS (Ostrove & Gifford, 1979) and
lymphotoxin (Kunitomi et al., 1975). However, physicochemical
characteristics distinguish TNS from lymphotoxin and other
°
cytostatic lymphokines: stable at 56°C, inactivated at 70 C
pH lability to both acid and base, with a pH maximum of 8.0
(Kull Cuatrecasas, 1981a) cytotoxicity is not inhibited by
the treatment with protease inhibitors. Inhibitors of energy
metabolism enhance sensitivity to lymphotoxin whereas they do
not enhance sensitivity to TNS (Kull & Cuatrecasas, 1981b).
TNF and lymphotoxin are now known to be antigenically distinct
molecules. TNF activity on L929 cells is not inhibited by
neutralizing antibodies specific for lymphotoxin (Gray et al.,
1984)However, the general similarities in the mechanisms of
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lymphotoxin and TNS raise the possibility that these
activities may constitute a common antiproliferative leukocyte
canabilitvs
MODE OF TUMOR NECROSIS FACTOR ACTION
Many studies on the action of TNF were performed with
crude serum (for review see Ruff and Gifford, 1981a). Hence,
they are subject to certain reservations that the effects of
TNF may have some contribution from contaminants present in
TNF-containinq serum.
The stuay or L-m cells aerivea LEOm LIle L7GJ C.:C11
(Darzynkiewicz et al., 1984) has shown that the immediate
effect of TNF is cytostasis, manifested as cell arrest in G2
phase of cell cycle. Shortly thereafter, the cytolytic effect
become apparent extensive cell lysis can be detected after 7
hr of exposure to TNF. After 24 hr nearly all cells are
lysed. Most cells undergo lysis specifically at late stages
of mitosis (telophase) or soon after cytokinesis. Nonlysed
cells from cultures treated with TNF do not show any changesin
nuclear chromatin, suggesting that neither DNA nor nuclear
proteins are the primary targets of TNF, and metabolic changes
which occur during mitosis (cytokinesis) may be responsible
for increased cell sensitivity towards the cytolytic effect of
TNF. Cytoskeletal disrupting agents (colchicine, Colcomid,
and cytochalasin B)and inhibitors of lysosome activity
(chloroquine, methylamine) are found to depress sensitivity.
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The results suggest that TNF entity may need to be
internalized and that lysomal activity may be necessary for
antitumor effect of TNFO Similar results were obtained by
Matthews and Watkins (1978). The use of antimetabolites such
as sodium azide and dinitrophenol partially protects L cells
from TNF (Matthews Watkins, 1978) and the failure of rabbit
0
TNF to kill L cells at 21 C suggest that the actively
metabolizing cells have higher sensitivity to TNF or there is
a possible enzymatic role of TNFG However, exact antitumor
mechanisms of TNF is stil unknown and await more
investigation.
Fung et al. (1985) have shown that Ehrlich ascites tumor
(EAT) cells were highly susceptible to the TNS prepared by
Corynebacterium parvum priming mice and elicited by LPS of E.
Coli. The cytotoxic effect of TNS on EAT cells, as shown by
3
[ H]-thymidine release assay, started as early as 4 hr after
incubation with TNS. TNS also inhibited EAT growth in mice in
vivo and inhibit the glucose transport of EAT cells both in
vivo and in vitro.
AIM OF STUDY
Since we have previously found out that mouse TNF can
suppress glucose transport activity in Ehrlich ascites tumor
cells, we continued the experiment on the study if TNF exerted
the same effect on glucose transport activity of L929 cells as
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in the EAT cells. A report by Matthews (1983) inaicates tnac
anti-tumor cytotoxin produced by human monocytes suppresses
the respiration rate and increases the glycolytic and glucose
uptake activities of L929 cells. Hence, it is interesting to
investigate if the mouse TNF can exert similar effect on
glucose transport activities of L929 cells. The study by
Kull and Cuatrecasas (1981b) shows that sensitivity of L-M
cells to TNF increases with elevated temperature and the
presence of inhibitors (cycloheximide, actinomycin D) of RNA
and protein synthesis. Ostrove and Gifford (1979) suggested
that it might be due to hampered repair mechanisms of the L
cells or possibly to a decrease in the synthesis of a
substance which competed with TNS. Kull and Cuatrecasas
(1981a) also suggested that the protein synthesis inhibitors
(actinomycin D or cycloheximide) might weaken the targets by
some sublethal injury, which was not directly exploited by TNS
but acted synergistically to enhance toxicity. We
investigated the effect of cycloheximide on TNS efficacy
against L929 cells in our experiment. Also included in the
experiment was the comparison of effects of TNS produced by
different priming agents, namely, BCG zymosan
Corynebacterium parvum Listeria monocytogenes and
Mxjrnharterium lepraemurium on the glucose transport activity.
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EXPERIMENTAL
PRODUCTION OF TUMOR NECROSIS SERUM (TNS)
Mice were injected intraperitoneally (i.p.) with 0.2 ml
saline containing 1 mg Corynebacterium parvum or zymosan. The
mice were challenged with 25 ug lipopolysaccharide W. (LPS)
from E. coli. in 0.2 ml saline intravenously (i.v.) 7 days
later. Mice were bled from subclavian vessels 90 min after
LPS injection. Listeria-TNS was similarly obtained from mice
injected i.v. with 10 4 Listeria in 0.2 ml saline.
Mycobacterium lepraemurium (MLM)-TNS was obtained from mice
injected i.p. with 5 x 108 bacteria 2 months before LPS
challenges (Ha et al., 1983). Control sera were obtained from
Listeria-, C. parvum-, or LPS-injected mice. Pooled sera were
incubated at 56 °C for 30 min to inactivate complement
components and sterilized by filtration through 0.45 um
°
sterile millipore filter and stored at -20 C until use.
TNS ON VIABILITY AND MORPHOLOGY OF L929 CELLS
10-' L929 cells were seeded in 24-well culture plate
(Falcon, New York) and incubated in the presence of 1.25%
(v/v) control serum, 2.5 ug/ml cycloheximide, 1.25% (v/v) TNS,
or both 1.25% (v/v) TNS and 2.5 ug/ml cycloheximide
respectively for 24 hr. The medium then was aspirated and 0.1
ml trvnan blue was added. The viability and morphology of the
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cells were studied under microsocpe.
[3 H]-THYMIDINE RELEASE ASSAY
L929 cells were grown in culture medium for 24 hr in the
presence of 25 uCi/ml [3H]-thymidine (41 Ci/mmol, Amersham).
Cells were washed three times with sterile PBS and resuspended
in growth medium at a concentration of 5 x 105 cells/ml. 0.1
ml cell suspension was added to each well of 96 well titre-
plate containing O.lml 2% control serum, 2.5 ug/ml
cycloheximide, 2% TNS, or 2% TNS with 2.5 ug/ml cycloheximide
respectively at desired concentration. The mixture was
incubated at 37 C for indicated time intervals and then 100 ul
of supernatant was taken and added to 0.7 ml of Triton X-100-
toluene scintillant. 100% releasable radioactivity (total
cpm) was measured by incubating labelled cells in 0.5% sodium
dodecylsulfate (SDS) for 30 min. Radioactivity was counted in
a Beckman LS 7000 liquid scintillation counter. Percentage[
3H]-thymidine released was calculated as:
H-Thymidine release
Experimental cpm- Control cpm
x 100
Total cpm- Control cpm
TNS ON 2-DEOXY-D-[3H]-GLUCOSE UPTAKE OF L929 CELLS
The 2-deoxy-D-glucose uptake of L929 cells were
determined as described in Chapter 3.
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EFFECT OF TNS ON PROTEIN CONTENT OF L929 CELLS
The L-cells, at 10b cells/ml, were incubated in the wells
of a 24-well plastic tissue culture plate (Falcon) with 0.5 ml
medium alone, or medium supplemented with 2% (v/v) C. parvum-
TNS, or with 2% (v/v) LPS control serum for 24 hours. The
cells then were trysinized with 0.1 ml 0.25% trypsin for 5 min
0
at 37 C. 0.4 ml medium was added and the cells were
dispersed. Then the cells were transferred to culture tubes
and spinned down by a table top clinical centrifuge. The
collected cells were washed once with saline and resuspended
with saline into 0.5 ml. 0.2 ml of the suspension was used




EFFECT OF TNS ON VIABILITY AND MORPHOLOGY OF L929 CELLS
The effect of TNS on the growth of L929 cells was
examined. Incubation of cultured L929 cells with 1.25% (v/v)
C. parvum-TNS for 24 hours increased the mortality of the
cells. Dead cells appeared as dark spots (DS) with trypan
blue stain in Fig. 6.1B. For those cells which were still
alive, there appeared some dark granules within the cells.
The incubation of L cells with TNS in the presence of 2.5
ug/ml cycloheximide even hampered the viability of the cells
(Fig. 6.1C). The cells have lost their integrity and rounded
up to death. On the other hand, the incubation of cells with
cycloheximide alone (Fig. 6.1D) had no significant effect on
the cells as compared with control (Fig. 6.1A).
CYTOLYTIC EFFECT OF TNS
The cytotoxic effect of TNS on L929 cells was monitored
by[ 3 H]-thymidine release assay to ensure the integrity of
cell membrane for glucose uptake measurement. The results in
Fig. 6.2 indicate that [3H]-thymidine release was detectable
after 24 hours of incubation. There was a progressive
increase in the amount of radioactivity released into the
medium from 24 to 50 hours. Hence, in the following
ovnArmPnf., the cells were usually incubated with TNS for 24
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Fig. 6.1 The effect of C. parvum-TNS on the viability
and morphology of L929 cells.
Cells were cultured in RPMI complete medium
supplemented with A) Control Serum 1.25% (v/v)
B) C. parvum-TNS
1.25% (v/v)
C) TNS, 1.25% and 2.5 ug/ml
cycloheximide
D) Cycloheximide, 2.5 ug/ml
for 24 hours. Medium was then aspirated and
0.1 ml trypan blue was added. Dead cells









Fig. 6.2 Effect of C. parvum-TNS on L929 cells.
Cells were incubated in RPMI complete medium
supplemented with 0.5% (v/v) TNS. [3H]-Thymidine
release was monitored as described in the text.











hours. Fig 6.3 shows the [3H]-thymidine release assay of the
above four groups (in Fig. 6.1). The results show that for
the control, cycloheximide and TNS groups, there is no
3
significant release of[ 3H]-thymidine before 24 hours.
However, the release of [3H]-thymidine in TNS+ cycloheximide
group was significantly higher than other groups.
EFFECT OF TNS ON GLUCOSE TRANSPORT OF EAT CELLS
The glucose uptake of cultured Ehrlich ascites tumor
cells under the effect of TNS were carried out to compare the
result with that obtained by L cells. The results (Table
6.1) shows that the 2-deoxy-D-glucose uptake of cultured EAT
cells incubated with 0.5% (v/v) of TNS was significantly lower
than the control serum.
EFFECT OF TNS ON 2-DEOXY-D-[JH1-GLUCOSE UPTAKE OF L929-CELLS
The 2-deoxy-D-glucose uptake of cultured L cells was
carried out as decribed in Chapter 3. Fig. 6.4 shows the
result of a typical experiment. Since the conventional
cytochalasin B binding method (Chan et al., 1983) cannot be
used in L929 cells (see Appendix I), the extent of the
diffusion-mediated uptake can be estimated graphically by
drawing a line through the origin and parallel to the linear
portion of the total uptake curve (Renner, Plagemann &
Bernlohr, 1972; Plagemann & Richey, 1974). The uptake rate
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due to the transport reaction was obtained by subtracting the
estimated diffusion rate due to the unsaturable component from
the overall rate. The corrected rates showed the Michaelis
type kinetics.
Fig. 6.5 shows the time kinetics of 2-deoxy-D-[3 H]-
glucose uptake of L929 cells incubated with RPMI medium
supplemented with or without 2% control serum respectively.
Control serum was obtained by injecting 25 ug/ml LPS to mice.
There was no great difference for the time-profile of cells
incubating in media with or without control serum incubation.
This indicates that control serum will not affect the glucose
transport experiments.
Fig. 6.6 shows a typical experiment on the determination
.of glucose transport rate of C. parvum-induced TNS treated
L929 cells and Table 6.2 shows the kinetic parameters of 2-
deoxy-D-glucose uptake for control and these TNS treated
cells. The maximal 2-deoxy-D-glucose uptake rate (Vmax) of
the C. parvum treated group shows a two-fold increase of Vmax
value comparing with control (Fig. 6.6 and Table 6.2). The
apparent half-saturation constant for the specific transport
process,Km, of TNS arouo exhibited small chanqes (Table 6.2).
EFFECT OF TNS ON PROTEIN CONTENT IN L929 CELLS
Since the 2-deoxy-D-glucose uptake of L929 cells was
Pxoressed in terms of nmol/mg protein instead of cell number,
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an experiment was carried out to examine the protein content
of L cells incubated for 24 hours in medium, or medium
supplemented with 2% LPS (control) serum, or with 2% C.
parvum. induced TNS. The results (Table 6.3) show that there
was no difference between protein content of TNS treated cells
and cells from control serum or medium groups. The increase
of uptake rate of glucose in TNS-treated cells are not due to
the decrease of protein content after treatment.
COMPARISON OF TNS FROM DIFFERENT PRIMING AGENTS ON GLUCOSE
t1PTAKF ACTIVITY OF L929 CELLS
The effects of TNS produced from different priming
agents, namely zymosan, Listeria and Mycobacterium
lepraemurium (MLM), on the 2-deoxy-D-[3 HI-glucose uptake
activity of L929 cells were compared (Table 6.4). Except MLM-
TNS, TNS produced from other two priming agents could increase
significantly the Vmax value of uptake activity (P< 0.001).
However, all preparations of TNS did not affect greatly the Km
value of the uptake process. It should be noted that TNS
induced by C. parvum (Table 6.2), zymosan and Listeria (Table
6.4) could exhibit about two-fold increases on glucose
transport rate (Vmax) of cultured L929 cells. Both TNS have
little effect on the nature of transport (expressed by Km
values) of the cells.
134
Fig. 6.3 Time kinetics of cytolytic effect of media
complemented with 2% C. parvum-TNS (0-0) or
2.5 ug/ml cycloheximide (- ) or 2% C.
parvum-TNS+ 2.5 ug/ml cycloheximide (0-0).
[ 3 H]-Thymidine release was monitored as
described in the text.












Table 601 Effect of TNF on glucose uptake activity of




Control serum 30.7 3.1 1.16+ 0.3
TNS 11.0+ 2,6* 1.14+ 0.2
a Cultured EAT cells were incubated with 0.5% (v/v) of
the appropriate serum at 37 °C. Harvested cells
were examined for their ability to take up glucose as
described in the text.
b Data are presented as mean+ S.E.M. for triplicate
determinations. Significance of difference between




Fig. 6.4 The determination of uptake rate due to the
transport reaction in L929 cells.
The curve for total uptake rate against
various concentrations of 2-deoxy-D-glucose
was plotted(•-•). The extent of
diffusion-mediated uptake can be estimated
graphically by drawing a line through the
origin and parallel to the linear portion of
the uptake curve. The uptake rate due to
the transport reaction (O-O) was obtained
by subtracting the estimated diffusion rate













Fig. 6.5 The time kinetics of 2-deoxy-D-glucose uptake
of L929 cells incubated with RPMI medium
supplemented with or without control serum.
Cells were incubated with RPMI medium(•---•)
or 2% (v/v) control serum (serum of mice
receiving LPS only) (0-0) for 24 hours.
2-deoxy-D-glucose uptakes of both groups were
performed at the indicated times of
incubation.










0 20 40 60
Time (min)
141
Fig. 6.6 The time kinetics of 2-deoxy-D-glucose uptake
of L929 cells incubated in RPMI media
supplemented with control serum or C. parvum-
induced TNS.
Cells were incubated with control serum
(2% v/v) ( ), C. parvum-induced serum
(2% v/v)( --) for 24 hours at 37 C. The
diffusion-mediated uptakes are presented as(
O) and () for control serum and TNS
respectively. The uptake of 2-deoxy-D-glucose
was measured for the indicated time intervals.













Table 6.2 The effects of C. parvum induced TNS on 2-
a
deoxy-D-glucose uptake of L929 cells.
Groups vmax Km
(nmol/min/mq protein) (mm)
Control 1.18+ 0.31 0.11+ 0.08
2.24+ 0.56C. parvum-TNS 0.50+ 0.20
(2%)
a The details of 2-deoxy-D-[3H]-glucose uptake of L929
cells were as described in the text.
The results are presented as mean± S.E.M. of
determinations of 2 experiments.
The significance was determined by Student's t-test.
* P< 0.005
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Table 6.3 The effect of TNS on the protein content of
a
L929 cells.
Supplement in Protein content per cell
RPMI Medium (ng protein/ cell)
None 0.875+ 0.158
Control Serum (2% LPS Serum) 0.909+ 0.172
0.915+ 0.114C. parvum-TNS (2%)
a The procedures are as described in the text.
The data are presented as mean+ S.E.M. of 6
determinations.
The significance of difference was determined by
Student's t-test.
# P >0.1 as compared with results obtained from
cells incubated with RPMI medium only.
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Table 6.4 The effect of TNS from different priming
agents on the uptake kinetics of 2-deoxy-D-
glucose of L929 cells.a
Groups Vmax Km
(nmol/min/mg protein) (mM)
Control 3.25+ 0.47 0.18+ 0.06
Zymosan-TNS 6.90+ 0.43* 0.38+ 0.04
*
Listeria-TNS 6.07+ 0.48 0.70+ 0.05
MLM-TNS 3.83+ 0.20# 0.21+ 0.05
a TNS induced by zymosan, Listeria, and Mycobacterium
lepraemurium (MLM) were prepared as described in
Experimental section in the text.
The details of 2-deoxy--D-[3H]-glucose uptake of
L929 cells were as described in the text.






L929 cells have. been reported to be very sensitive to TNS
(Carswell et al., 1975 Matthews Watkins, 1978) and has been
used for in vitro TNF assay. From our results (Fig. 6.1) we
can find that TNF is effective against the viability of L
cells. It has been reported that TNS cytotoxicity, measured
by the release of[ 3H]-thymidine or 51Cr from labeled L929
cells, could be detected only after 8- 12 hours of incubation
(Ruff Gifford, 1981b Matthews Watkins, 1978). Our
results (Fig. 6.2)'also support this suggestion. Our results
also demonstrated that combined use of TNS and cycloheximide
can enhance the cytotoxic effect of TNF (Fig. 6.1C). The cells
after incubating with medium supplemented with 1.25% (v/v) TNS
and 2.5 ug/ml cycloheximide for 24 hours, have lost their
integrity and rounded up to death (Fig. 6.1C). The cytotoxic
effect of TNS in the presence of cycloheximide was further
proved by the [3H]-thymidine release assay. As indicated in
3
Fig. 6.3, while less than 10% of[ H]-thymidine were released
from TNS-treated or cycloheximide-treated cells as compared
3
with control in 24 hours incubation, nearly 55%[ H]-thymidine
release was observed in TNS+ cycloheximide treated cells
after 24 hours incubation. The findings that the anti-tumor
effect of TNS in vitro can be enhanced in the presence of
cycloheximide suggests a more sensitive method for the
estimation of TNS titer by using L cells. It is also of
interest to examine whether this synergistic effect of TNF and
cycloheximide on tumor cells also apperas in experimental
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animals.
In EAT cells, the treatment of C. parvum-induced TNS can
inhibit the uptake of glucose significantly (Table 6.1 and
Fung et al., 1985). In contrast, the uptake of 2-deoxy-D-
glucose increases in C. parvum-induced TNS treated L cells
(Table 6.2). This discrepancy is difficult to explain. One
possible explanation is that TNF induced by C. parvum might
have different actions on EAT cells and L cells. In order to
test whether there is any contaminate in the serum that might
affect the glucose carrier of L cells, we examined the glucose
uptake profile of L cells incubating in plain RPMI medium and
medium supplemented with control serum (produced by LPS
injection only). Fig. 6.5 indicats that the glucose uptake in
both situations were in similar profile. To further study
whether the increase in Vmax values of L cells is unique in C.
parvum-induced TNF, we also tested TNFs produced from
different sources. Table 6.4 shows that both Listeria-induced
and zymosan-induced TNS could increase Vmax of glucose uptake
in L cells. It is also interesting to note that the increases
of Vmax in L cells after C. parvum-, zymosan- and Listeria-
induced TNF's treatments are relatively similar, with the
ranr a at Ahniit 2 folds.
Matthews (1983) has reported that the treatment of L
cells with cytotoxin from human monocytes can decrease the
respiration rate and increase the rate of glycolysis and
glucose uptake in the tumor cells. The mitochondrial
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dysfunction after cytotoxin treatment might cause the
increased rate of glucose utpake and glycolysis which is
considered to be a compensatory action of the tumor cells to
counteract this stress. We do not know the action mechanism
of TNF, and we have not measured the respiration rate of L
cells and therefore cannot be sure the same change has
happened in the L cells after the incubation with TNS.
Our observations that the binding of cytochalasin B is
not displaceable by D-glucose (Appendix I) suggests the
difference between the glucose uptake properties of L929 cells
and Ehrlich ascites tumor cells. This kind of lack of
inhibition of cytochalasin B binding by glucose as observed in
L929 cells, also occurs in macrophages and lymphocytes (see
Appendix I). We may conclude by saying that the glucose
uptake properties and the nature of cytochalasin B binding are
not universal for all kinds of cells. The difference between
glucose uptake activities in L cells and Ehrlich ascites tumor
cells is at best one of the examples. However, we do not know
the action mechanism of TNS on the tumor cells. The
difference of the glucose uptake activity in L cells and
Ehrlich ascites tumor cells may just be the manifestation of
different action of TNS on the cells. In appendix I, we
studied the effect of TNS on the permeability of membrane of L
cells. Results indicate that TNF treated L cells also
exhibitded increases of uridine and Ca uptake. We are now
in the progress to study whether similar changes would occur
in TNS-treated Ehrlich ascites tumor cells.
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CHAPTER SEVEN
THE EFFECT OF ANTIMETABOLITES ON THE GLUCOSE TRANSPORT OF
L929 AND EHRLICH ASCITES TUMOR CELLS
INTRODUCTION
There are many antitumor agents which have been
extensively studied for their cytotoxic effects. These
antitumor agents include methotrexate (Hryniuk, 1972
Kaminskas Nussey, 1978 Ernst, 1971 Lala Patt, 1966), N-
(phosphonacetyl)-L-aspartate (PALA) (Baillon et al., 1983
Plageman Richey, 1974 Tsuboi Kwong, 1978 Collins
Stark, 1971), tumor necrosis factor (TNF) (Matthews, 1983
Carswell et al., 1975 Matthews Watkins, 1978 Green et al.,
1977 Ha et al., 1985 Fung et al., 1985), interferon and
interferon inducers (Kleinschmidt, 1972 Gresser et al., 1970
Nagano Takano, 1982 DuBy, 1972 DeClercq, 1981
Stringfellow, 1981 Riviere Hovanessian, 1984). Most of
these antitumor agents are thought to have inhibitory effects
on DNA, RNA and protein synthesis of tumor cells and hence
exhibit the tumor inhibitory effects.
The tumor models we employed are L929 and Ehrlich ascites
tumor cells. Since Ehrlich ascites tumor cells depend
primarily on glycolysis for the provision of energy and to
m,n4- nn nrnx.th nntPntial, it is essential that they possess a
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highly efficient system for glucose transport and metabolism
(Chan et al., 1983 Leung et al., 1984 Fung et al., 1985).
Since the carrier mediating the glucose transport is a protein
(Cuppoletti, Mayhew Jung, 1981), a hypothesis has been
raised by us during our studies of methotrexate, PALA and TNF
on Ehrlich ascites tumor cells that the depletion of
nucleotides by these antitumor drugs and the consequent
inhibition of DNA, RNA and protein synthesis might have
constituted the primary chain of events leading to reduced
carrier production. In order to prove this hypothesis, we
studied the effects of two commonly used antimetabolites,
namely cycloheximide and actinomycin D on the glucose
transport of tumor cells. Cycloheximide has an inhibitory
effect on protein synthesis in cytosol ribosomes, whereas
actinomycin D inhibits RNA synthesis by intercalating between
DNA bases, especially in G-C rich regions. It is conceivable
that they might have certain effect on glucose carrier
synthesis during tumor cell growth.
AIM OF STUDY
In this chapter, the experiments of the effects of
cycloheximide and actinomycin D on glucose transport
activities of L929 and Ehrlich ascites tumor cells are
described. The effects of both antimetabolites on the
precursors incorporation of EAT cells are also discussed.
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EXPERIMENTAL
PREPARATION OF DRUG SOLUTION
Cycloheximide and actinomycin D were dissolved in PBS (pH
7.4) at concentration of 0.45 mg/ml. The reconstituted
solution was stored in freezer until use. The solution was
diluted to the desired concentrations with PBS and used
directly for injection.
TREATMENT OF TUMOR BEARING MICE
Mice were inoculated i.p. with 2 x 106 Ehrlich ascites
tumor cells harvested from 7-day old tumors in 0.2 ml PBS on
day 0. The effects of cycloheximide and actinomycin D were
observed -in groups of at least 10 mice each. In the test
groups, cycloheximide and actinomycin D (0.9 ug/mouse or 1.8
ug/mouse) were administered intraperitoneally in 0.2 ml PBS on
days 2, 4 and 6 inclusively. The mice were sacrified by
cervical dislocation on day 7. Tumor cells were washed 5
times with half-isotonic saline to remove blood cells and
harvested by centrifugation. The final cell suspension was
prepared in PBS. Cells were counted with a haemocytometer and
7
resuspended in the same buffer to 2 x 10 cells/ml. Glucose
uptake and cytochalasin B binding were then measured as
described in Chapter 3. For the determinations of
incorporation of leucine, uridine and thymidine, the cells
6
wPrP resuspended in PBS to 10 cells/ml and the methods as
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described in Chapter 3 were followed.
TREATMENT OF L929 CELLS
5
10 L929 cells were incubated in 0.5 ml complete RPMI
1640 medium with 2.5 ug/ml cycloheximde or complete medium at
37 C for 24 hours. Then the glucose uptake experiment was
carried out as described in Chapter 3 and Chapter 6.
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RESULTS
THE EFFECTS OF ANTIMETABOLITES ON TUMOR SIZE OF EAT CELLS
The effects of cycloheximide and actinomycin D on tumor
size of Ehrlich ascites tumor in tumor-carrying mice were
studied (Table 7.1). The results show that cycloheximide is
not effective in reducing tumor size whereas actiromycin D can
reduce the tumor size by 20% (P<0.01) at dose 0.9 ug/mouse.
When the dose is raised to 1.8 ug/mouse, both antimetabolites
are effective in reducing EAT tumor size. Cycloheximide can
reduce the tumor size by 23% (P <0.05), whereas actinomycin D
can reduce the tumor size by 70% (P <0.001).
EFFECTS OF ANTIMETABOLITES ON THE GLUCOSE TRANSPORT OF EAT
CELLS
Both the 2-deoxy-D-[3H]-glucose uptake and cytochalasin B
binding were carried out to assay the effects of cycloheximide
and actinomycin D on the glucose transport activity of Ehrlich
ascites tumor cells. The results (Table 7.2) show that
actinomycin D at dose 1.8 ug/mouse was effective in decreasing
both 2-deoxy-D-[ 3 H]-glucose maximal uptake rate (Vmax) and
glucose-sensitive cytochalasin B binding (Bo). The Vmax value
was significantly reduced by half (P< 0.02) and the Bo value
reduced by 65% (P< 0.001). The Km and Kd values showed no
great change in values. However, cycloheximide at dose 1.8
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ug/mouse did not show any significant reduction in Vmax and Bo
values (P >0.02).
EFFECTS OF ANTIMETABOLITES ON PRECURSORS INCORPORATION IN
AT CELLS
Cycloheximide group (1.8 ug/mouse) showed a reduction in
leucine incorporation (P< 0.001), suggesting that protein
synthesis was inhibited. However, the incorporation of
thymidine and uridine were increased. The actinomycin D group
(1.8 ug/mouse) showed a significantly great reduction in the
incorporation of leucine (60%), thymidine (50%) and uridine
(30%).
EFFECT OF CYCLOHEXIMIDE ON 2-DEOXY-D-[3 H]-GLUCOSE UPTAKE OF
L929 CELLS
The results shown in Table 7.4 indicate that 2.5 ug/ml
cycloheximide did not show any effect on the glucose uptake
rate (P <0.1) of the L cells culture and the Km values of
control culture and cycloheximide treated culture did not show
any great difference.
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Table 7.1 The in vivo effects of both antimetabolites on
a
tumor growth of EAT cells.
Treatment Tumor size(% of Control)
Cycloheximide (0.9 ug/mouse) 100.22+ 23.06
Cycloheximide (1.8 ug/mouse) 77.69+ 27.20
* *
Actinomycin D (0.9 ug/mouse) 80.14+ 13.74
* * *
Actinomycin D (1.8 uq/mouse) 31.65+ 8.95
a The details of experiment are as described in the
text.
The significance of difference between test and
control groups was determined by Student's t-test.




as compared with control.
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Table 7.2 The in vivo effects of antimetabolites on
glucose transport activity of EAT cells.a
Cytochalasin B binding2-deoxy-D-glucose uptake
KdBoKmVmaxGroups







a The details of experiment are as described in the
text.
Significant differences: * P < 0.001
** P < 0.02
# not significant
as compared with control.
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Table 7.3 The in vivo effects of antimetabolites on
precurors incorporation in EAT cells.a
Treatment % Incorporation b
Leucine Thymidine Uridine
Cycloheximide 81.78 ± 6.78***127.01 ± 20.92* 146.36 ± 40.53**
(1.8 ug/mouse)
Actinomycin D 43.25 ± 16.00*** 49.13 ± 34.07** 70.52 ± 29.09#
(1.8 ug/mouse)
a The details of experiment are described in the text.
b Assuming the incorporation of control group is 100%
Significant differences: *** P < 0.001
** P < 0.02
* P < 0.05
# P < 0.05
as compared with control.
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Table 7.4 In vitro effect of 2.5 ug/ml cycloheximide on





0.24 + 0.041011± 0065#Cycloheximide
a The details of the experiment are as described in the
text.




It has been postulated that the depletion of
macromolecules necessary for the production of glucose carrier
would lead to defects in glucose transport activity of Ehrlich
ascites tumor cells (Chan et al., 1983 Leung.et al., 1984
Fung et al., 1985). This conclusion has further proved by the
results of the present study. Actinomycin D which inhibits
RNA synthesis by intercalating the DNA bases has a drastic
effect of suppressing both tumor size and glucose transport
activity of EAT cells (Table 7.1 and 7.2). The reduction of
tumor size paralleled the reduction in both the maximal uptake
rate and glucose-sensitive cytochalasin B binding. Since only
the Vmax and Bo values were reduced and no significant changes
in Km and Kd values, we suggest that the destructive effect of
actinomycin D is on the quantities of carrier on the cell
membrane. While alteration in the turnover rate of the
glucose carriers cannot be absolutely ruled out in the present
study, its contribution to the overall transport process is at
best minimal. The results of precursors incorporation also
support this conclusion (Table 7.3). The incorporation of all
precursors have been significantly reduced in actinomycin D
treated EAT cells and this suggests that DNA, RNA and protein
synthesis have been impaired. The defects of protein
synthesis would consequently affect the number of glucose
carriers and then the glucose uptake. The result of
cvcloheximide may show that the inhibition of protein
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synthesis have not been completed. The reduction of leucine
incorporation is only 20% and there are no reductions in other
precursors incorporation (Table 7.3). The lack of inhibition
of the dose of cycloheximide (1.8 ug/mouse) under test on the
glucose transport activities (Table 7.2) can also be compared
with the small effect of the same dose of drug on tumor growth
(Table 7.1)
The minimal antitumor effect of cycloheximide observed in
Ehrlich ascites t.umor bearing mice was re-examined in vitro
with another tumor line, L929. The treatment with 2.5 ug/ml
cycloheximide is also ineffective in decreasing the glucose
uptake of cultured L929 cells.
From the results of above experiments, we may conclude
that the effect of actinomycin D on the glucose transport
process in Ehrlich ascites tumor cells is due to the reduction
in glucose carrier number. This effect parallels with the
antitumor effect of actinomycin D on the tumor size of EAT.
The small antitumor effect of cycloheximide on tumor size may
be due to its lack of efficacy in affecting the glucose
transport system in Ehrlich ascites tumor. Similar effect has
been obtained by the treatment of cycloheximide on L929 cells.
It is also conceivable that suppression of RNA synthesis is an
important mechanism of anti-tumor agents which can inhibit
tumor growth by reducing glucose carriers of the tumor cells.
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CHAPTER EIGHT
GENERAL CONCLUSION AND OUTLOOK
The effects of some anticancer agents on the glucose
transport system, especially on the glucose uptake of L929 and
Ehrlich ascites tumor cells were investigated in this thesis.
EFFECTS OF THYMIDINE AND URIDINE RESCUE ON METHOTREXATE-
TREATED EHRLICH ASCITES TUMOR CELLS
The effect of methotrexate on glucose carrier in Ehrlich
ascites tumor cells has been studied in our previous work
(Chan et al., 1983). It has been proposed that the direct
effect of methotrexate is on the inhibition of nucleotide
synthesis through the impairment of folate system and
induction of a purineless state in cells (Hryniuk, 1973).
To further investigate the underlying action mechanism of
methotrexate and to examine the effectiveness of exogenous
thymidine rescue for tumor cells, we studied the reversal
effect of thymidine in methotrexate treated Ehrlich ascites
tumor cells. The results show that the tumor cells, after
thymidine administration in vivo and in vitro, can partially
recover the growth capability, glucose uptake rate and glucose
carrier number to the status before the methotrexate
treatment. Hoglind-Semon and Grindey (1978) suggested that
the mechanism if thvmidine rescue for normal cells is through
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the metabolic conversion of thymidine to thymidine-5'-
triphosphate and decreased rate of thymidylate synthetase.
The decreased rate of thymidylate synthetase would not deplete
the tetrahydrofolte pool whose production has already been
inhibited by methotrexate. We postulated that this rescue
mechanism appearing in normal cells might also take place in
tumor cells. Since Ehrlich ascites tumor cells have a
comparatively large number of glucose carriers on their
membrane than other cells (Chan et al., 1983) and these
glucose carriers are protein in nature (Cuppoletti, Mayhew and
Jung, 1981), the inhibition of methotrexate on nucleotide and
the consequent inhibition of DNA, RNA and protein synthesis
may have constituted primary chain of events leading to
reduced glucose carrier production (Chan et al., 1983). The
protection of exogenous thymidine on nucleotide synthesis
would therefore relieve the chain of inhibition. This
suggestion is supported by the results of our experiment that
the rescue of thymidine of tumor cells are accompanied by
partial reversal of methotrexate on the maximal glucose uptake
rate (Vmax) and glucose-sensitive cytochalasin B binding (Bo),
without affecting the Michaelis constant (Km) of glucose
uptake and apparent dissociation constant of glucose-sensitive
cvtochalasin B binding (Kd), of the tumor cells.
The ineffectiveness of exogenous uridine in methotrexate
rescue on tumor cells might be due to the production of
rlonYx,-„rrlnP-Si-monophosphate by the cells through the salvage
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process and aggrevate the impaired folate system by enhancing
the reaction of thymidylate synthetaseo The possible rescue
of tumor cells by the administration of purine or pyrimidine
or their analogs and their effects on glucose transport of
tumor cells are also worth studying.
EFFECTS OF INTERFERON INDUCERS ON EAT CELLS
The results of interferon inducers also support our
suggestion of primary chain of action of anticancer agents on
glucose carrier of Ehrlich ascites tumor cells. The
administration of Poly I:C, tilorone and statolon can
effectively reduce the tumor size and also the number of
glucose carrier and the uptake rate. However, information
about the action mechanism of these interferon inducers is
still lacking. The interferon titer in the sera of treated
mice we obtained 24 hours after administration of inducers was
quite low. The production of interferon might have already
been inhibited by the immune system of the outbred mice.
Therefore we suggested the use of inbred mice in the
experiment and the earlier collection of serum (2-4 hours
after the administration of inducers) might minimize the
degradation and hyporeactivity effects.
The admininstration of interferon inducers (i.p.) near
the tumor site (i.p.) is more effective in reducing the tumor
size than other routes of administration. Similar results
have been obtained by DuBuy (1972) and Gresser Bourali
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(1970). The difference of effectiveness might be due to the
direct effect of local interferon induced or the direct effect
of the inducers on the tumor. It has been postulated that the
antitumor effects of inducers like Poly I:C do include direct
chemotherapeutic effect or host-mediated reaction besides the
action of interferon induced (Talal, 1971 Levy et al., 1970).
The effectiveness of Poly I:C treatment before the
inoculation of tumor is a promising direction for the
discovery of a low toxic precautionary drug against some
spontaneous high-risk tumor. The DEAE:Poly I:C Complex and
the Poly (ICLC) developed which possess greater quantity of
interferon production and higher resistance of enzymatic
degradation may be a promise to this direction (Pitha &
Carter, 1970 DeClercq, 1981). Should these highly efficient
interferon inducers have more pronounced effect of the glucose
transport of tumor cells is also of interest to investigate.
EFFECT OF TNS ON GLUCOSE UPTAKE OF L929 CELLS
The effects of TNS produced by different priming agents
show an increase in 2-deoxy-D-glucose uptake rate of L929
cells. Since the effect of TNS on L cells observed by
Darzynkiewicz et al. (1984) is the initial cytostatic and the
later cytolytic response, the increased glucose uptake rate
might be responsible for the increased division rate and the
consequent death of the cells after a long time of incubation
with TNS. However, the underlying action mechanism of TNS is
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still obscure. The contrasting results of the effect of TNS
on Ehrlich ascites tumor (Fung et al., 1985) may suggest
different responses of tumor cells to TNS or the nature of
glucose carrier of these two tumor cells might be different.
EFFECT OF ANTIMETABOLITES ON L929 AND EAT CELLS
The antitumor effects of cycloheximide and actinomycin D
were investigated. Actinomycin D showed an inhibitory effect
on tumor growth, glucose uptake and carrier number of Ehrlich
ascites tumor cells. The conclusion is similar to that
purposed by us in our previous work that the inhibition of
macromolecules synthesis would lead to impairment of protein
synthesis and consequently the reduction of glucose carrier
number in Ehrlich ascites tumor cells. The mechanism
concerning the inability of cycloheximide in arresting tumor
growth and glucose uptake rate in L929 and Ehrlich ascites
tumor cells awaits further examination.
SCOPE OF FURTHER STUDY
In the present study, we have shown that methotrexate,
interferon inducers and tumor necrosis factor are effective in
suppressing Ehrlich ascites tumor growth and reducing glucose
carrier number. Our previous studies have indicated that PALA
(Leung et al., 1984), BCNU and CCNU (Leung et al., unpublished
data) have similar property. Whether the effect of reduction
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of glucose carrier is a primary or secondary reaction of
these anti-tumor agents on the glucose carrier protein remains
unknown.
In order to test the primary effect of these agents on
the glucose carrier of the tumor cells, we plan to purify the
glucose carrier of the cell and to test the effects of drugs
on the glucose transport status of the liposome composed of
the glucose carrier. Concerning the secondary effect of these
anti-tumor agents on the glucose transporter of tumor cells,
we have demonstrated in this thesis that the inhibition of DNA
and/or RNA and/or protein synthesis might be one of the
factors. Other factors included: (1) the possible effect of
these agents on the translocation of glucose, carrier from
microsomal pool to the plasma membrane of the tumor cells
(2) the possible effect of these agents on the control of
intracellular concentration of purines which have been
reported to be a hyper-repressor of glucose carrier in chick
fibroblasts (Gay Amos, 1983) (3) the possible effect of
these agents on the control of intracellular concentration of
phosphoribosyl diphosphate (PPRibP) has also been reported to
be inversely correlated to the glucose transport rate in chick
fibroblasts (Gay & Amos, 1983).
Concerning the factor (1), we are now in the progress in
studying the possibility of using the photoaffinity labelling
with[ H]-cytochalasin B (Carter-Su et al., 1982 Shanahan,
1QR2) fn mnnitnr the chanqe of the contents of carriers on
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plasma membrane and intracellular fractions. Concerning the
factors (2) and (3), we plan to study both the relationship
between the intracellular concentrations of purine and PPRibP
on the glucose transport of Ehrlich ascites tumor cells and L
cells in vivo and in vitro.
The diversified effects of TNS on Ehrlich ascites tumor
cells and L cells are also worth studying. Firstly, we plan
to investigate more clearly the nature of the glucose carrier
on L929 cells. Secondly, we plan to purify TNF from the sera
of mice receivng C. parvum and lipopolysaccharide so that no
contaminant might take place in our determinations. Thirdly,
we will extend our investigation of the effect of TNF to other
tumor cell lines with the hope of further understandng of the
actual mechanism of TNF on tumor cell growth.
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APPENDIX I
GLUCOSE REVERSIBILITY OF CYTOCHALASIN B BINDING IN
SOME CELLS
ABSTRACT
Several tumor or normal cell lines were found to have
cytochalasin B binding which cannot be displaced by high molar
of glucose solution. Among all cell lines tested, binding of
cytochalasin B either in the absence or in the presence of 500
mM glucose was the same. Cytochalasin B, thereafter, cannot
be used as universal marker for glucose carriers on the
surface of cells.
INTRODUCTION
Cytochalasin B is a mold metabolite isolated from
Helminthosporium dematioideum. Besides the ralative long term
effect on the microfilaments of the cells (Wessells et al.,
1971), it was found to be a potent, reversible inhibitor of
glucose uptake in many normal cells such as human erythrocytes
(Sogin Hinkle, 1980), adipocytes (Karnieli et al., 1981) and
chick embryo fibroblasts (Salter & Weber, 1979) and some tumor
cells such as HeLa cells (Lin et al., 1974), Ehrlich ascites
rmnr cells (Cuooletti et al., 1981 Chan et al., 1983) and
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Novikoff rat hepatoma (Graff et al., 1981). A set of high-
affinity glucose-reversible binding sites for cytochalasin B
has been identified to be the glucose transporters of these
cells. Studies performed on this glucose-reversible
cytochalasin B binding activity in the above cell systems
reveal that they share a common characteristics: (1) a high
affinity for cytochalasin B (Kd values in the range of 1- 6 x
-7
10 M) (2) reversibility of binding by 500 mM glucose.
Cytochalasin B binding method has now been widely used to
estimate the density of glucose carrier of different cells
(see Chapter 1 for review).
Most recently, Albert (1984) found that the binding of
cytochalasin B and the rabbit erythrocytes could not be
displaced by glucose and they claimed that cytochalasin B does
not serve as a marker of glucose transporter in rabbit
erythrocytes. In our study of glucose transport system of L
cells (Chapter 6), we also found that the binding of
cytochalasin B on L cells could not be replaced by 500 mM
glucose. We report our results on L cells herein and results




L929, mice thymocytes, spleen cells and peritoneal
macrophages were employed for the test.
L929 cells were cultured in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine,
5 mg/ml glucose,' 50 units/ml penicillin and 100 ug/ml
streptomycino The medium was buffered with 25 mM HEPES and 25
mM NaHCO
The thymocytes and spleen cells were collected from the
thymus and spleens of female ICR mice respectively. Tissues
were minced and the cells were obtained by pressing through a
50 mesh wire gauze to form a single cell suspension. Blood
cells in spleen cell preparations were lysed by incubating the
cells in ammonium-tris HC1 buffer (pH 7.2) at room temperature
for 15 min. Cells were washed three times in PBS before use.
Viability of cells always exceeded 95% by trypan blue
Ayr-1 vision test.
Peritoneal macrophages were obtained from female mice
injected i.p. with 0.5 mg C. parvum 7 days prior to sacrifice.
Each animal was lavaged with 10 ml ice-cold saline and cells
were pooled from groups of 60 mice. Differential count of
3
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cell suspension using Wright's stain showed that more than 85%
of cells were non-specific esterase positive and 80% were
phagocytic (Ha et al., 1984). The cells were washed twice in
PBS before doing cytochalasin B binding experiment.
CYTOCHALASIN B BINDING OF L929 CELLS
L929 cells which have reached confluency in 24-well
plastic tissue culture plate (Falcon) was washed twice with
PBS (pH 7.2) and equilibrated to 37 C. 0.04 uCi 3[ H]-
cytochalasin B and 2 x l0-7 M cytochalasin B in volume of 0.5
ml was added to the cells and incubated to the indicated time
intervals. For the non-specific binding, 500 mM D-glucose was
present in the incubation medium in another plate. The
incubation was stopped by aspiration of supernatant and
washing with cold saline. Cells were lysed by addition of 0.5
ml 0.1% Triton X-100 to individual well. Radioactivity of the
lysate was counted in a Beckman LS-7000 liquid scintillation
counter and protein was determined by Lowry's method.
CYTOCHALASIN B BINDING OF THYMOCYTES, SPLEEN CELLS AND
PERITONEAL MACROPHAGES
The details of cytochalasin B binding are the same as
thnsc described in Chapter 3 for Ehrlich ascites tumor cells.
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RESULTS
CYTOCHALASIN B BINDING OF L929 CELLS
The time kinetics of cytochalasin B binding in the
presence and absence of 500 mM glucose are shown in Fig. I.l.
The results indicate that the binding of cytochalasin B is not
displaceable by large quantity (500 mM) of D-glucose. The
binding of L cells begin saturation at about 10 min. in the
absence of glucose. However, the binding of cytochalasin B is
still increasing after 20 min for the L cells when 500 mM
glucose is present. These obervations imply that the glucose
carrier of L cells cannot be estimated by cytochalasin B
bindinq method.
CYTOCHALASIN B BINDING OF THYMOCYTES, SPLEEN CELLS AN
PERITONEAL MACROPHAGES
Fig. 1.2 shows the% bound of cytochalasin B versus
different concentrations of cytochalasin B in spleen
cells and thymocytes in the absence and in the presence of 500
mM glucose. The cytochalasin B binding sites in both cells
seem to be not affected by the presence of 500 mM glucose.
Thymocytes have only a half% bound when compared with spleen
cells. The result of cytochalasin B binding experiment of
peritoneal macrophages (Fig. 1.3) gave similar% bound to
that of spleen cells and was also glucose non-displaceable.
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Fig. I.1 The time kinetics of cytochalasin B binding of
L929 cells in the presence (0-C) and the
absence(•---•) of 500 mM D-glucose.
The details of cytochalasin B binding are
described in the text.











Fig. 1.2 The % bound of cytochalasin B binding versus
concentrations of cytochalasin B in spleen
cells in the presence (0--0) and absence(
•---•) of 500 mM glucose; and thymocytes in
the presence (---) and absence(----) of
500 mM glucose respectively.
The detailed procedures for cytochalasin B











Fig. 1.3 The% bound of cytochalasin B binding versus
concentration of cytochalasin B in peritoneal
macrophages in the presence (0--O) or
absence (-) of 500 mM glucose.
The detailed procedures for cytochalasin B











The present results indicate that cytochalasin B binding
may not be displaceable by D-glucose in all cell types. The
cytochalasin B binding in human erythrocytes (Jung Rampal,
1977), transformed chicken embryo fibroblasts (Salter Weber,
1979) and Ehrlich ascites tumor cells (Cuppoletti et al.,
1981), which can be easily displaced by glucose, thereafter,
is different from the binding in L929, thymocytes, spleen
cells and peritoneal macrophages. The cytochalasin B binding
sites in the latter group may not necessarily be the glucose
carrier although the uptake of 2-deoxy-D-glucose in L cells
can be effectively inhibited by cytochalasin B (results
The binding site may be in
unpublished in our laboratory).
the vicinity of glucose uptake site and the existence of
ochalasin B may sterically inhibit the uptake of 2-deoxy-D-
cyt
glucose, and therefore the binding of cytochalasin B on L
cells cannot be affected by the existence of glucose molecules
(Fig. I.l). The lack of glucose-sensitive cytochalasin B
binding in L cells, mouse thymocytes, spleen cells and
peritoneal macrophages may show the fact that the glucose
uptake properties and the nature of cytochalasin B binding are
not universal for all kinds of cells. Similar findings were
Albert (1984) on rabbit erythrocytes and our
reported by




EFFECT OF TUMOR NECROSIS SERUM ON MEMBRANE PERMEABILITY OF
L929 CELLS
INTRODUCTION
When we studied the effect of tumor necrosis serum (TNS)
on the glucose carrier of tumor cells, we found that TNS could
reduce glucose uptake and density of glucose carrier in
Ehrlich ascites tumor cells while enhancement of total glucose
uptake was observed in TNS treated L929 cells (Chapter 6).
Since the glucose carriers of L cells could not be estimated
by cytochalasin B binding method (Appendix I), it is difficult
for us to explain this paradoxical effect of TNS on different
tumor cells. Since increase in total glucose uptake in TNS-
treated L cells might be the result of increasing glucose
simple diffusion or glucose transport mediated by glucose
carrier, it is reasonable to study the change of cell membrane
after TNS treatment. Furthermore, we are aware of
of L cells
no previous studies which examined the biochemical mechanism
of action of TNS on cell membrane. The present study would
more detailed information for further understanding of
give
the mechanism of antitumor effect of TNF.
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EXPERIMENTAL
[3H]-URIDINE UPTAKE OF L929 CELLS
The procedures for uridine uptake of L929 cells was
similar to the procedures for 2-deoxy-D-glucose uptake of L929
cells (Chapter 3). 1.0 L cells, in 0.5 ml complete RPMI 1640
medium, were incubated with control serum or TNS for 24 hours
0
at 37 C. The monolayer of L929 cells then was washed twice
0
with PBS and equilibrated to 37 C. At time zero, 0.5 ml
prewarmed [3 H]-uridine (100 uCi/umol) in PBS was added to give
final concentrations of 25- 100 uM. Reaction was stopped
after 1 min by aspirating off the medium and rapid washing
the cells twice with 1 ml ice-cold PBS supplemented with 0.05M
uridine. The unsaturable diffusion was estimated by the
presence of 20 uM (final concentration) of inhibitor
dipyridamole or S-p-nitrobenzyl-6-thioguanosine (NBTGR) in the
incubation medium. The cells were lysed by addition of 0.5 ml
0.1% Triton X-100 to individual well. Radioactivity of the
lysate was counted in a Beckman LS-7000 liquid scintillation
counter. Protein was determined by Lowry's method.
45 2+
Ca UPTAKE
105 L929 cells, in 0.5 ml complete RpMI 1640 medium, were
0
incubated with different dilutions of mouse sera at 37 C for
24 hours. The monolayer was then washed twice with plain
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RPMI. At various time intervals, 0.4 ml prewarmed 45 Ca 2+ -
containing RPMI medium (0.7 mM, 0.076 uCi/well; 16.2 uCi/mM)
was added to each well. Reaction was stopped by aspiration
off the medium and rapid washing the cells three times with
ice-cold saline containing 4 mM LaC1 to replace Ca2+ bound to
the extracellular glycocalyx. Finally the cells were
solubilized by adding 0.5 ml 1% Triton X-100. Radioactivity
of the lysate was counted in a Beckman LS-7000 liquid
scintillation counter. Protein was determined by Lowry's
method.
[3 H]-METHIONINE UPTAKE AND 14 C-LEUCINE UPTAKE
Uptake of [3 H]-methionine (0.1 mM; 89 Ci/mmol) and 14 C-
leucine (0.38 mM; 342 mCi/mmol) by L cells was carried out as
for 45 Ca 2+ uptake except that 0.02 uCi 14 C-leucine and 2 uCi
[3 H]-leucine/0.4 ml RPMI medium was added to each well of
culture plate. Reaction was stopped by using saline without
LaC13.
RESULTS
EFFECT OF TNS ON URIDINE TRANSPORT
Fig. II.1 shows the results of a typical experiment of
[3H]-uridine by L929 cells in vitro. The rate of simple
diffusion into the cells was obtained by simultaneous addition
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of 20 uM dipyridamole or 20 uM NBTGR. Both dipyridamole and
3
NBTGR can inhibit the facilitated uptake of[3 H]-uridine by
L929 cells. The subtraction of uptake in the presence of
inhibitor (i.e. unsaturable diffusion) from the total uptake
in the absence of inhibitor will give the facilitated uptake
of L cells (Fig. II.1B). The rate of facilitated uptake was
rapid and linear in the first 1 min. The effect of TNS on the
uridine uptake of L929 cells is shown in Fig. 11.2. Cells
treated with 1% TNS (v/v) have a significantly greater rate of
simple diffusion than cells treated with control serum.
EFFECT OF TNS ON 45 Ca2+ UPTAKE
To investigate whether the action of TNF created an ionic
imbalance within the target L929 cells, cellular uptake rate
of CaCl was determined. Fig. 11.3 shows that addition of
2
TNS significantly increased the 45 Ca 2+ uptake rate by L929
cells.
EFFECT OF TNS ON AMINO ACIDS UPTAKE
To examine if TNS had a gross effect of membrane
permeability of L929 cells, the 14 C-leucine and 3 H-methionine
transport systems of TNF treated L929 cells were investigated.
Fig. II.4 and Fig. II.5 show that neither 14 C-leucine nor3 H-
methionine uptake rates was altered in TNF treated L929 cells.
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Fig. II.1 The time kinetics of [3H]-uridine uptake of
L929 cells incubated in RPMI medium.
II.1A [3 H]-uridine uptake in the absence (●—●),
or in the presence of 20 uM NBTGR (○—○),
or 20 uM dipyridamole (☆—☆).
II.1B The facilitated uptake by subtracting the
uptake in the presence of 20 dipyridamole
from the total uptake in Fig. II.1A.
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Fig. II.2 Effect of TNS on [3H]-uridine uptake of L929
cells.
L929 cells, incubated with medium in the
absence of(•--•), or in the presence of(
O--O) 20 um (final concentration)
dipyridamole or incubated with medium
supplemented with 1% (v/v) C. parvum-TNS for
24 hr in the absence of ( ), or in the
presence of 20 uM dipyridamole ( ).
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Fig. II.3 Time kinetics of 45Ca2+ uptake of L929 cells
incubated with media supplemented with 2%
(v/v) control serum(•--•), or with 2% (v/v)
C. parvum-TNS (O---O) for 24 hr before the
uptake experiment.
The procedures of uptake are described in the
text.












Fig. 11.4 Time kinetics of14 C-leucine uptake for L929
cells incubated in media supplemented with
2% control serum(•-•) or with 2% C.
parvum-TNS for 24 hr before the uptake
experiment( 0- 0).















Fig. 11.5 Time kinetics of [3H]-methionine uptake of L929
cells incubated in media with 2% control serum
(.-.) or with 2% C. parvum-TNS (0- 0).
for 24 hr. before the uptake experiment.












One of the basic questions concerning the mechanism of
TNF-mediated cytolysis is whether TNF has a primary action
site on the tumor cellular membrane, thus inducing structural
and/or functional alternations of membrane, or whether the TNF
molecule is incorporated into the cell, thus interupting
primarily are of the intracellular metabolic pathways which
are essential for normal cell growth. The experiments
presented here were designed to explore, biochemically, the
nature of the TNF-induced damage(s) to the plasma membrane of
L929 cells. The results indicate that cells treated with TNS
had a signifant increase in rate of simple diffusion of[ 3 H]-
uridine as compared to that of cells treated with control
serum (Fig. II.2). The active component of [3 H]-uridine
uptake was, however, unaltered. Furthermore, we also found
that the 45Ca2+ uptake rate was also observed to increase
after TNS treatment. This increase in 45Ca2+ uptake rate
during TNS action might indicate a failure of the Ca
extruding mechanism or Ca influxing mechanism. Though we
cannot differentiate between these two possible mechanism of
TNF on L929 cells, we can draw a tentative conclusion that TNF
might cause a change of permeability on membrane of L929
cells.
It is of interest to note that the total upcaxe rates
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of two structurally related amino acid, leucine and methionine
were not altered by TNS (Fig. 11.3 and II.4). These findings
suggest that TNS can selectively affect the rate of uptake of
some biochemicals, for example, glucose, uridine and45Ca21,
and the other active transport systems are not necessarily
affected. In this respect, lymphotoxin has been reported to
have similar effect on L cells. Okamato and Mayer (1978)
2+
reported that Ca2+ uptake rate was increased while the K+
uptake rate, amino acid uptake rate (as determined by
aminoisobutyrate uptake) and dye exclusion ability were the
same, in lymphotoxin treated L cells. Most recently, TNF and
lymphotoxin are reported to be similar structurally (Gray et
al., 1984). It is conceivable that these two antitumor agents
might have similar actions on L cells.
However, data presenting in Chapter 6 and here still
cannot indicate whether the TNS-induced changes of membrane
permeability in L cells, resulting in enhanced uptake rate of
certain biochemicals, is a primary or a secondary phenomenon.
The TNS preparations used in these studies were still not
purified. Therefore, there remains a possibility that the
2+
increase of the glucose, uridine and Ca2+ uptake rate in L929
cells might be induced by some contaminant. An answer to this
question will be obtained only when highly purified
nrPnarations of TNF become available for study.
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